WO2018027106A2 - RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION - Google Patents

RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION Download PDF

Info

Publication number
WO2018027106A2
WO2018027106A2 PCT/US2017/045446 US2017045446W WO2018027106A2 WO 2018027106 A2 WO2018027106 A2 WO 2018027106A2 US 2017045446 W US2017045446 W US 2017045446W WO 2018027106 A2 WO2018027106 A2 WO 2018027106A2
Authority
WO
WIPO (PCT)
Prior art keywords
rnai agent
hbv
antisense strand
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/045446
Other languages
English (en)
French (fr)
Other versions
WO2018027106A3 (en
Inventor
Zhen Li
Rui ZHU
Christine I. Wooddell
Bruce D. Given
Tao Pei
David L. Lewis
Lauren J. Almeida
David B. Rozema
Darren H. Wakefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Pharmaceuticals Inc
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2017306692A priority Critical patent/AU2017306692B2/en
Priority to EA201990427A priority patent/EA201990427A1/ru
Priority to CR20220468A priority patent/CR20220468A/es
Priority to MX2019001493A priority patent/MX2019001493A/es
Priority to KR1020197006273A priority patent/KR102500675B1/ko
Priority to PE2023003074A priority patent/PE20250393A1/es
Priority to KR1020237005107A priority patent/KR102540359B1/ko
Priority to BR112019002117-5A priority patent/BR112019002117A2/pt
Priority to IL264575A priority patent/IL264575B2/en
Priority to CA3032945A priority patent/CA3032945A1/en
Priority to CR20220469A priority patent/CR20220469A/es
Priority to US15/766,036 priority patent/US10780108B2/en
Priority to EP17837738.8A priority patent/EP3494123B1/en
Priority to CR20190056A priority patent/CR20190056A/es
Priority to CN201780061911.7A priority patent/CN109843902B/zh
Priority to MYPI2019000637A priority patent/MY199749A/en
Priority to KR1020247009034A priority patent/KR102774202B1/ko
Priority to ES17837738T priority patent/ES2988612T3/es
Priority to CN202310672003.9A priority patent/CN116514890A/zh
Priority to KR1020237018497A priority patent/KR102650107B1/ko
Priority to IL305507A priority patent/IL305507A/en
Priority to NZ750390A priority patent/NZ750390B2/en
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Priority to EP24162143.2A priority patent/EP4364808A3/en
Priority to SG11201900910TA priority patent/SG11201900910TA/en
Priority to JP2019505172A priority patent/JP7237816B2/ja
Publication of WO2018027106A2 publication Critical patent/WO2018027106A2/en
Publication of WO2018027106A3 publication Critical patent/WO2018027106A3/en
Priority to PH12019500245A priority patent/PH12019500245A1/en
Priority to US16/267,194 priority patent/US20190255091A1/en
Anticipated expiration legal-status Critical
Priority to CONC2019/0002017A priority patent/CO2019002017A2/es
Priority to US16/990,916 priority patent/US11590156B2/en
Priority to US17/529,107 priority patent/US11517584B2/en
Priority to JP2022015856A priority patent/JP2022068222A/ja
Priority to AU2022205929A priority patent/AU2022205929B2/en
Priority to US18/074,268 priority patent/US20230355651A1/en
Priority to JP2023090659A priority patent/JP7625637B2/ja
Priority to JP2024115530A priority patent/JP2024150603A/ja
Priority to AU2024219418A priority patent/AU2024219418A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • RNA interference (RNAi) agents for inhibition of Hepatitis B Virus gene expression, compositions that include HBV RNAi agents, and methods of use thereof.
  • HBV Hepatitis B Virus
  • Hepatitis B Virus is classified as one member of the Hepadnaviruses and belongs to the family of Hepadnaviridae. The primary infection of adult humans with Hepatitis B Virus causes an acute hepatitis with symptoms of organ
  • ccc covendedly closed circular
  • the cccDNA serves as a template for transcription of five major viral niRNAs, which are 3.5, 3.5, 2.4, 2.1 and 0.7 kb long. All mRNAs are 5'-capped and polyadenylated at the 3 '-end. There is sequence overlap at the 3'-
  • One 3.5 kb rnRNA serves as template for core protein and polymerase production.
  • the same transcript serves as a pre-genomic replication intermediate and allows the viral polymerase to initiate the reverse transcription into DNA.
  • Core protein is needed for nucleocapsid formation.
  • the other 3.5 kb mRNA encodes pre-core, the secretable e-antigen (HBeAg).
  • HBeAg secretable e-antigen
  • the 2.4 and 2.1 kb mRNAs earn 7 the open reading frames ("ORF") pre-S l, pre-S2 and S for expression of viral large, medium and small surface antigen.
  • the s-antigen is associated with infectious, complete particles.
  • blood of infected patients also contain non- infectious particles derived from s-antigen alone, free of genomic DNA or polymerase. The function of these particles is not fully understood.
  • the complete and lasting depletion of detectable s-antigen in blood is considered as a reliable indicator for Hepatitis B Virus clearance.
  • the 0.7 kb mRNA encodes the X protein. This gene product is important for efficient transcription of viral genes and also acts as a transactivator on host gene expression.
  • a second treatment option is the administration of interferon -alpha.
  • patients receive high doses of interferon-alpha over a period of 6 months.
  • the Asian genotype B gives very poor response rates.
  • Co-infection with Hepatitis D Virus (HDV) or Human I mmunodeficiency Virus has been shown to render interferon-alpha therapy completely ineffective. Patients with strong liver damage and heavy fibrotic conditions are not qualified for interferon-alpha therapy.
  • RNAi Hepatitis B Virus-specific RNA interference
  • dsRNA double-slranded ribonucleic acid
  • RNAi agents also herein termed RNAi agent, RNAi trigger, or trigger
  • HBV Hepatitis B Virus
  • the described HBV RNAi agents can be used in methods for therapeutic treatment and or prevention of symptoms and diseases associated with H BV infection, including but not limited to chronic liver diseases/disorders, inflammations, fibrotic conditions, proliferative disorders (including cancers, such as hepatocellular carcinoma), Hepatitis D Virus (HDV ) infection, and acute HBV infection.
  • the HBV RNAi agents can be used in methods for therapeutic treatment and/or prevention of symptoms and diseases associated with chronic HBV infection and/or HDV infection.
  • Such methods comprise administration of one or more HBV RNAi agents as described herein to a subject, e.g., a human or animal subject.
  • compositions comprising one or more of the disclosed HBV RNAi agents that are able to selectively and efficiently decrease expression of an HBV gene.
  • the compositions comprisin one or more HBV RNAi agents can be administered to a subject, such as a human or animal subject, for the treatment and or prevention of symptoms and diseases associated with HBV infection.
  • Each HBV RNAi agent disclosed herein includes at least a sense strand and an antisense strand.
  • the sense strand and the antisense strand can be partially, substantially, or fully complementary to each other.
  • the length of the RNAi agent sense and antisense strands described herein each can be 16 to 30 nucleotides in length.
  • the sense and antisense strands are independently 17 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are independently 19 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are independently 21 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are independently 21 to 24 nucleotides in length. The sense and antisense strands can be either the same length or different lengths.
  • the HBV RNAi agents disclosed herein have been designed to include antisense strand sequences that are at least partially complementary to a sequence in the HBV genome that is conserved across the majority of known serotypes of HBV.
  • RNAi agents described herein upon delivery to a cell expressing HBV. inhibit the expression of one or more HBV genes in vivo or in vitro.
  • An HBV RNAi agent includes a sense strand (also referred to as a passenger strand) that includes a first sequence, and an antisense strand (also referred to as a guide strand) that includes a second sequence.
  • a sense strand of the HBV RNAi agents described herein includes a core stretch having at least about 85% identity to a nucleotide sequence of at least 16 consecutive nucleotides in an HBV mRNA.
  • the sense strand core nucleotide stretch having at least about 85% identity to a sequence in an HBV mRNA is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • An antisense strand of an HBV RNAi agent comprises a nucleotide sequence having at least about 85% complementary over a core stretch of at least 16 consecutive nucleotides to a sequence in an HBV mRNA and the corresponding sense strand.
  • the antisense strand core nucleotide sequence having at least about 85% complementarity to a sequence in an HBV mRNA or the corresponding sense strand is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • HBV RNAi agent sense strands and antisense strands that can be used in HBV RNAi agents are provided in Tables 3 and 4.
  • Examples of HBV RNAi agent duplexes are provided in Table 5.
  • Examples of 19-nucleotide core stretch sequences that consist of or are included in the sense strands and antisense strands of HBV RNAi agents disclosed herein, are provided in Table 2.
  • one or more HBV RNAi agents are delivered to target cells or tissues using any oligonucleotide delivery technology known in the art.
  • Nucleic acid delivery methods include, but are not limited to, by encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules. and bioadhesive microspheres, proteinaceous vectors or Dynamic Poly conjugates (DPCs) (see, for example WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, each of which is incorporated herein by reference).
  • an HBV RNAi agent is delivered to target cells or tissues by covalently linking the RNAi agent to a targeting group.
  • the targeting group can include a cell receptor ligand, such as an asialoglycoprotein receptor (ASGPr) ligand.
  • ASGPr asialoglycoprotein receptor
  • an ASGPr ligand includes or consists of a galactose derivative cluster.
  • a galactose derivative cluster includes an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer.
  • a galactose derivative cluster is an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer.
  • a targeting group can be linked to the 3' or 5' end of a sense strand or an antisense strand of an HBV RNAi agent. In some embodiments, a targeting group is linked to the 3' or 5' end of the sense strand. In some embodiments, a targeting group is linked to the ' end of the sense strand. In some embodiments, a targeting group is linked to the RNAi agent via a linker.
  • a targeting group, with or without a linker can be linked to the 5' or 3' end of any of the sense and or antisense strands disclosed in Tables 2. 3, and 4.
  • a linker, with or without a targeting group, can be attached to the 5 Or 3' end of any of the sense and/or antisense strands disclosed in Tables 2, 3, and 4.
  • compositions that include one or more HBV RNAi agents having the duplex sequences disclosed in Table 5.
  • compositions that include a combination or cocktail of at least two HBV RNAi agents having different nucleotide sequences.
  • the two or more different HBV RNAi agents are each separately and independently linked to targeting groups.
  • the two or more different HB V RN Ai agents are each linked to targeting groups comprised of N-acetyl-galactosamines.
  • each of the RNAi agents is linked to the same targeting group.
  • each of the RNAi agents is linked to different targeting groups, such as targeting groups having different chemical structures.
  • targeting groups are linked to the HBV RNAi agents without the use of an additional linker.
  • the targeting group is designed having a linker readily present to facilitate the linkage to an HBV RNAi agent.
  • the two or more RNAi agents may be linked to the targeting groups using the same linkers.
  • the two or more RNAi agents are linked to the targeting groups using different linkers.
  • compositions that include a combination of at least two HBV RNAi agents having different sequences, wherein each HBV RNAi agent targets a different location or different region of an HBV gene.
  • compositions that include a combination of at least two HBV RNAi agents, wherein each HBV RNAi agent is designed to target a different HBV transcript for example, a composition that includes two HBV RNAi agents, wherein the first HBV R Ai agent includes an antisense strand that is at least partially complementary to a nucleotide sequence located in the S ORF of an HBV gene, while the second HBV R Ai agent includes an antisense strand that is at least partially complementary to a nucleotide sequence located in the X ORF of an HBV gene).
  • an RNAi agent that includes an antisense strand at least partially complementary to a nucleotide sequence located in the S ORF targets a portion of the HBV genome of SEQ ID NO: I between positions 1-1307 and 3185-3221.
  • an RNAi agent that includes an antisense strand at least partially complementary to a nucleotide sequence located in the X ORF targets a portion of the HBV genome of SEQ ID NO: I between positions 1308-1930.
  • HB niRNA is known to be polycistronic, resulting in the translation of multiple polypeptides, and separate niRNAs overlap in RNA sequence, therefore a single RNAi agent targeting an HBV gene may result in inhibition of most or all HBV transcripts.
  • compositions that includes two or more HBV RNAi agents targeting different locations or regions of an HBV gene may provide for additional advantages over a composition that includes only a single HBV RNAi agent, such as (a) ensuring that all HBV viral transcripts are targeted (i.e., 3.5 kb p re-gen omic RNA; 3.5 kb pre-core mR A; 2.4 kb pre-S l mRNA; 2.1 kb pre-S2/S mRNA; 0.7 kb X mRNA; as well as any S-antigen expressing mRNAs produced from integrated HBV DNA); (b) serving to expand the genotype coverage to potentially address a larger patient population; and/or (c) potentially decreasing the viral resistance due to
  • compositions that include a combination of one HBV RNAi agent that targets the S ORF of an HBV RNA (i.e., having an antisense strand that targets the S transcripts (S, pre-Sl, and pre-S2), the pregenomic RNA (core and polymerase), and the pre-core transcripts (HBeAg) of an HBV genome), and one HBV RNAi agent that targets the X ORF of an HBV RNA (i.e., having an antisense strand that targets the X transcript of an HBV genome, the S transcripts (S, pre-Sl, and pre-S2), the pregenomic RNA (core and polymerase), and the pre-core transcripts (HBeAg) of an HBV genome), in some embodiments, the compositions described herein include at least one HBV RNAi agent that contains a sequence that targets the S ORF of an FIBV gene, and a second HBV RNAi agent that contains a sequence that targets
  • HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3.
  • HBV RNAi agents having a sense strand comprising the sequence of any of the sequences in Table 4.
  • HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3, and a sense strand comprising the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • HBV RNAi agents having an antisense strand that consists of the sequence of any of the sequences in Table 3, and a sense strand that consists of the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • HBV RNAi agents having the duplex structure of Table 5.
  • HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3.
  • HBV RNAi agents having a sense strand comprising the sequence of any of the sequences in Table 4.
  • HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3, and a sense strand comprising the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • Disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection the method comprising administering one or more HBV RNAi agents having an antisense strand that consists of the sequence of any of the sequences in Table 3, and a sense strand that consists of the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection the method comprising administering one or more HBV RNAi agents having the duplex structure of Table 5.
  • HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3
  • a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3.
  • a first HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the first HBV RNAi agent
  • a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the second HBV RNAi agent.
  • a first HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the first HBV RNAi agent
  • a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the second HBV RNAi agent.
  • an HBV RNAi agent disclosed herein comprises: a. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AUUGAGAGAAGUCCACCAC (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGUGGACUUCUCUCAAU (SEQ ID NO: 34); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UUUGAGAGAAGUCCACCAC (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGUGGACUUCUCUCAAA (SEQ ID NO: 35); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AAUUGAGAGAAGUCCACCA (SEQ ID NO: 12), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGGUGGACUUCUCUCAAUU (SEQ ID NO: 39); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUUGAGAGAAGUCCACCA (SEQ ID NO: 13), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGGUGGACUUCUCUCAAUA (SEQ ID NO: 40); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCC (SEQ ID NO: 17), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGACUUCUCUCAAUUUUCU (SEQ ID NO: 44); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGAAAAUUGAGAGAAGUCC (SEQ ID NO: 18), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGACUUCUCUCAAUUUUCA (SEQ ID NO: 45); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') ACCAAUUUAUGCCUACAGC (SEQ ID NO: 22), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) GCUGUAGGCAUAAAUUGGU (SEQ ID NO: 49); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGC (SEQ ID NO: 23), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GCUGUAGGCAUAAAUUGGA (SEQ ID NO: 50); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3') GACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) CUGUAGGCAUAAAUUGGUC (SEQ ID NO: 54); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUU (SEQ ID NO: 55); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3') UACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 56).
  • compositions for inhibiting expression of an HBV gene in a cell comprising an HBV RNAi agent.
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) AAUUGAGAGAAGUCCACCA (SEQ ID NO: 12), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) UGGUGGACUUCUCUCAAUU (SEQ ID NO: 39); or ii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUUGAGAGAAGUCCACCA (SEQ ID NO: 13), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGGUGGACUUCUCUCAAUA (SEQ ID NO: 40);
  • a second HBV RNAi agent comprises:
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUC (SEQ ID NO: 54); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUU (SEQ ID NO: 55); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 56).
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCC (SEQ ID NO: 17), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGACUUCUCUCAAUUUUCU (SEQ ID NO: 44); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGAAAAUUGAGAGAAGUCC (SEQ ID NO: 18), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) GGACUUCUCUCAAUUUUCA (SEQ ID NO: 45);
  • a second HBV RNAi agent comprises:
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) CUGUAGGCAUAAAUUGGUC (SEQ ID NO: 54); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3') AACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUU (SEQ ID NO: 55); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAG (SEQ ID NO:
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AAUUGAGAGAAGUCCACCA (SEQ ID NO: 12), and a sense strand that comprises the nucleobase sequence differing by 0, 1,
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5'-»3') UAUUGAGAGAAGUCCACCA (SEQ ID NO: 13), and a sense strand that comprises the nucleobase sequence differing by 0, 1,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCC (SEQ ID NO: 17), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) GGACUUCUCUCAAUUUUCU (SEQ ID NO: 44); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) UGAAAAUUGAGAGAAGUCC (SEQ ID NO: 18), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGACUUCUCUCAAUUUUCA (SEQ ID NO: 45);
  • a second HBV RNAi agent comprises an antisense strand having a sequence that is at least partially complementary to a portion of the X ORF of an HBV mRNA:
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand having a sequence that is at least partially complementary to a portion of the S ORF of an HBV mRNA, and wherein a second HBV RNAi agent comprises:
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUC (SEQ ID NO: 54); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5'-»3') AACCAAUUUAUGCCUACAG (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) CUGUAGGCAUAAAUUGGUU (SEQ ID NO: 55); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3') UACCAAUUUAUGCCUACAG (SEQ ID NO: 29), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 56).
  • an HBV RNAi agent disclosed herein comprises:
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) UACCAAUUUAUGCCUACAGGCCUUAU (SEQ ID NO: 149); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) UACCAAUUUAUGCCUACAGGCCU (SEQ ID NO: 150); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGGC (SEQ ID NO: 151); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGAAAAUUGAGAGAAGUC CUU (SEQ ID NO: 152); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) UAUUGAGAGAAGUCCACCACG (SEQ ID NO: 160); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 163); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) UAUUGAGAGAAGUCCACCACGA (SEQ ID NO: 170); or j. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCUU (SEQ ID NO: 1
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCCU (SEQ ID NO: 173); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') U AUUGAGAGAAGUC C AC C AUU (SEQ ID NO: 174); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUC CUU (SEQ ID NO: 178); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUC CACUU (SEQ ID NO: 1
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUC C AC C (SEQ ID NO: 180); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 181); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') ACCAAUUUAUGCCUACAGCUU (SEQ ID NO: 182); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGCUU (SEQ ID NO: 1
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 186); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCU (SEQ ID NO: 187); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AACCAAUUUAUGCCUACAGCC (SEQ ID NO: 189); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') ACCAAUUUAUGCCUACAGCCU (SEQ ID NO: 1
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGCCU (SEQ ID NO: 191); or
  • cc an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') ACCAAUUUAUGCCUACAGCCG (SEQ ID NO: 192); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGCCG (SEQ ID NO: 193); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGGG (SEQ ID NO: 194); and wherein the HBV RNAi agent further comprises a sense strand at least partially complementary to the respective antisense strand.
  • an HBV RNAi agent disclosed herein comprises:
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGGCCUUAU (SEQ ID NO: 149); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) UACCAAUUUAUGCCUACAGGCCU (SEQ ID NO: 150); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) UACCAAUUUAUGCCUACAGGC (SEQ ID NO: 151); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGAAAAUUGAGAGAAGUCCUU (SEQ ID NO: 1)
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') U AUUGAGAGAAGUC C AC C AC G (SEQ ID NO: 160); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 163); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUUGAGAGAAGUCCACCACGA (SEQ ID NO: 1
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCCU (SEQ ID NO: 1
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUUGAGAGAAGUCCACCAUU (SEQ ID NO: 174); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUC CUU (SEQ ID NO: 178); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUC CACUU (SEQ ID NO: 179); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUC C AC C (SEQ ID NO: 1
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 181); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') ACCAAUUUAUGCCUACAGCUU (SEQ ID NO: 182); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' 3') ACCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 183); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') ACCAAUUUAUGCCUACAGCCUC (SEQ ID NO: 184); or v. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGCUU (SEQ ID NO: 185); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGCCUU (SEQ ID NO:
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCU (SEQ ID NO: 187); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AACCAAUUUAUGCCUACAGCC (SEQ ID NO: 189); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') ACCAAUUUAUGCCUACAGCCU (SEQ ID NO: 190); or
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGCCU (SEQ ID NO: 1
  • cc an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') ACCAAUUUAUGCCUACAGCCG (SEQ ID NO: 192); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCCAAUUUAUGCCUACAGCCG (SEQ ID NO: 193); or.
  • an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGGG (SEQ ID NO: 194);
  • HBV RNAi agent further comprises a sense strand at least partially complementary to the respective antisense strand.
  • an HBV RNAi agent disclosed herein comprises: an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'- 3') usAfscCfaAfuUfuAfuGfcCfuAfcAfgGfccsusuAu (SEQ ID NO: 61); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfscCfaAfuUfuAfuGfcCfuAfcAfgGfcscsu (SEQ ID NO: 62); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfccsu (SEQ ID NO: 63); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfsc (SEQ ID NO: 64); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu (SEQ ID NO: 68); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'- 3') usAfscscaauUfuAfuGfcCfuacagcsc (SEQ ID NO: 85); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'->3') usAfsusugagAfgAfaGfuCfcaccacsg (SEQ ID NO: 94); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfgsa (SEQ ID NO: 98); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'- ⁇ 3') usAfscsCfaAfuuuauGfcCfuAfcAfgcsc (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'- 3') usAfscsCfaAfuuuauGfcCfuAfcAfgcusu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'- 3') usAfscsCfaAfuuuauGfcCfuAfcAfgccsu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0. 1 , 2 or 3 nucleotides from the sequence (5'- 3') usAfscsCfaAfuuuauGfcCfuAfcAfgccusu (SEQ ID NO: 105); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu (SEQ ID NO: 1
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'-»3') cPrpusAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfsg (SEQ ID NO: 108); or
  • an antisense strand that comprises the sequence differing by 0, 1 , 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfsusUfgAfgagaaGfuCfcAfcCfausu (SEQ ID NO: 109); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfsusUfgAfgagaaGfuCfcAfcCfacsg (SEQ ID NO: 110); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'- 3') usAfsusUfgAfgagaaGfuCfcAfcCfacsusu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfsusUfgAfgagaaGfuCfcAfcCfacsgsa (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfsusUfgAfgagaaGfuCfcAfcCfacusu (SEQ ID NO: 120); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') asGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu (SEQ ID NO: 125);
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') asGfsasAfaAfuUfgAfgAfaGfuCfcasc (SEQ ID NO: 126); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' - 3') asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacusu (SEQ ID NO: 127); or xxiii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacsc (SEQ ID NO: 128); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5 * -»3 * ) usGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5*-»3*) asCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusc (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5 * -»3 * ) usCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1 , 2 or 3 nucleotides from the sequence (5*-»3*) usCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' -»3") cP ⁇ usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc (SEQ ID NO: 136); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'-»3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc (SEQ ID NO: 137); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'->3') cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc (SEQ ID NO: 138); or xxxiv. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsg (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') asAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usAfscsCfaAfuUfUfAfuGfcCfuAfcAfgusu (SEQ ID NO: 142); or
  • an antisense strand that comprises the sequence differing by 0, 1. 2 or 3 nucleotides from the sequence (5'- 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgCfsc (SEQ ID NO: 143); or
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') asCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1 , 2 or 3 nucleotides from the sequence (5 * -»3 * ) usCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1 , 2 or 3 nucleotides from the sequence (5*-»3') asCfscAfaUfuUfaUfgCfcUfaCfaGfccsg (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5' ⁇ 3') usCfscAfaUfuUfaUfgCfcUfaCfaGfccsg (SEQ ID NO:
  • an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5'-»3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfggsg (SEQ ID NO:
  • a, g, c and u are 2'-0-methyl (2'-OMe) modified nucleotides; Af, Cf, Gf, and Uf are 2'-fluoro modified nucleotides; s is a phosphorothioate intemucleoside linkage and the remaining nucleotide monomers are linked by phosphodiester bonds; and cPrpu is 5'- cyclopropyl phosphonate-2'-0-methyl modified nucleotide; and wherein the HBV RNAi agent further comprises a sense strand at least partially complementary to the respective antisense strand.
  • an HBV RNAi agent disclosed herein comprises:
  • an antisense strand that consists of the sequence (5'- 3') usAfscCfaAfuUfuAfuGfcCfuAfcAfgGfccsusuAu (SEQ ID NO: 61); or ii. an antisense strand that consists of the sequence (5'->3') usAfscCfaAfuUfuAfuGfcCfuAfcAfgGfcscsu (SEQ ID NO: 62); or
  • an antisense strand that consists of the sequence (5'->3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfccsu (SEQ ID NO: 63); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfsc (SEQ ID NO: 64); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu (SEQ ID NO: 68); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscscaauUfuAfuGfcCfuacagcsc (SEQ ID NO: 85); or
  • an antisense strand that consists of the sequence (5'- 3') usAfsusugagAfgAfaGfuCfcaccacsg (SEQ ID NO: 94); or
  • an antisense strand that consists of the sequence (5'->3') usAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfgsa (SEQ ID NO: 98); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuuuauGfcCfuAfcAfgcsc (SEQ ID NO: 102); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuuuauGfcCfuAfcAfgcusu (SEQ ID NO: 103); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuuuauGfcCfuAfcAfgccsu (SEQ ID NO: 104); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuuuauGfcCfuAfcAfgccusu (SEQ ID NO: 105); or
  • xiii an antisense strand that consists of the sequence (5'- 3') cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu (SEQ ID NO: 107); or xiv. an antisense strand that consists of the sequence (5'->3') cPrpusAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfsg (SEQ ID NO: 108); or xv.
  • an antisense strand that consists of the sequence (5'- 3') usAfsusUfgAfgagaaGfuCfcAfcCfausu (SEQ ID NO: 109); or xvi. an antisense strand that consists of the sequence (5'- 3') usAfsusUfgAfgagaaGfuCfcAfcCfacsg (SEQ ID NO: 110); or
  • an antisense strand that consists of the sequence (5'- 3') usAfsusUfgAfgagaaGfuCfcAfcCfacsusu (SEQ ID NO: 11 1); or
  • an antisense strand that consists of the sequence (5'- 3') usAfsusUfgAfgagaaGfuCfcAfcCfacsgsa (SEQ ID NO: 112); or
  • an antisense strand that consists of the sequence (5'->3') usAfsusUfgAfgagaaGfuCfcAfcCfacusu (SEQ ID NO: 120); or
  • an antisense strand that consists of the sequence (5'->3') asGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu (SEQ ID NO: 125);
  • an antisense strand that consists of the sequence (5'- 3') asGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO: 126); or
  • an antisense strand that consists of the sequence (5'- 3') asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacusu (SEQ ID NO: 127); or
  • an antisense strand that consists of the sequence (5'- 3') asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacsc (SEQ ID NO: 128); or
  • an antisense strand that consists of the sequence (5'- 3') usGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu (SEQ ID NO: 129); or
  • an antisense strand that consists of the sequence (5' ->3') usGfsas AfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO : 130); or
  • an antisense strand that consists of the sequence (5' - 3') asCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu (SEQ ID NO: 131); or
  • an antisense strand that consists of the sequence (5'- 3') asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu (SEQ ID NO: 132); or
  • an antisense strand that consists of the sequence (5' - 3') asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusc (SEQ ID NO: 133); or
  • an antisense strand that consists of the sequence (5' ->3') usCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu (SEQ ID NO: 134); or
  • an antisense strand that consists of the sequence (5'- 3') usCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu (SEQ ID NO: 135); or
  • an antisense strand that consists of the sequence (5'->3') cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc (SEQ ID NO: 136); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc (SEQ ID NO: 137); or xxxiii. an antisense strand that consists of the sequence (5'- 3') cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc (SEQ ID NO: 138); or xxxiv. an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsu (SEQ ID NO: 139); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsg (SEQ ID NO: 140); or
  • an antisense strand that consists of the sequence (5'->3') asAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc (SEQ ID NO: 141); or
  • an antisense strand that consists of the sequence (5'->3') usAfscsCfaAfuUfUfAfuGfcCfuAfcAfgusu (SEQ ID NO: 142); or
  • an antisense strand that consists of the sequence (5'- 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfgCfsc (SEQ ID NO: 143); or
  • an antisense strand that consists of the sequence (5'- 3') asCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu (SEQ ID NO: 144); or
  • an antisense strand that consists of the sequence (5'- 3') usCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu (SEQ ID NO: 145); or
  • an antisense strand that consists of the sequence (5'- 3') asCfscAfaUfuUfaUfgCfcUfaCfaGfccsg (SEQ ID NO: 146); or
  • an antisense strand that consists of the sequence (5'->3') usCfscAfaUfuUfaUfgCfcUfaCfaGfccsg (SEQ ID NO: 147); or
  • an antisense strand that consists of the sequence (5' - 3') usAfscsCfaAfuUfuAfuGfcCfuAfcAfggsg (SEQ ID NO: 148);
  • a, g, c and u are 2'-0-methyl (2'-OMe) modified nucleotides; Af, Cf, Gf, and Uf are 2'-fluoro modified nucleotides; s is a phosphorothioate intemucleoside linkage and the remaining nucleotide monomers are linked by phosphodiester bonds; and cPrpu is 5'- cyclopropyl phosphonate-2'-0-methyl modified nucleotide; and wherein the HBV RNAi agent further comprises a sense strand at least partially complementary to the respective antisense strand.
  • an HBV RNAi agent disclosed herein comprises:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UUGCCUGUAGGCAUAAAUUGGUAUT (SEQ ID NO: 275); or b. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUAUGCCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 276); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 1
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CGUGGUGGACUUCUCUCAAUU (SEQ ID NO: 285); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CGUGGUGGACUUCUCUCAAUA (SEQ ID NO: 289); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UCGUGGUGGACUUCUCUCAAUU (SEQ ID NO: 1)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1. 2 or 3 nucleobases from the sequence (5' ⁇ 3') GCUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 303); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGCUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 304); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 306); or m. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AAUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 1)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGACUUCUCUCAAUUUUCU (SEQ ID NO: 318); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 319); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGACUUCUCUCAAUUUUCA (SEQ ID NO: 320); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCA (SEQ ID NO: 321); or
  • s. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GCUGUAGGCAUAAAUUGGU (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 323); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GAGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 324); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GCUGUAGGCAUAAAUUGGA (SEQ ID NO: 325); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 326); or x. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 327); or
  • y a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 1
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5'-»3 * ) GGCUGUAGGCAUAAAUUGGUU (SEQ ID NO: 329); or
  • an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 330); or
  • bb a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 331); or
  • cc. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 332); or
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CGGCUGUAGGCAUAAAUUGGA (SEQ ID NO:
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') CCCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 334);
  • HBV RNAi agent further comprises an antisense strand at least partially complementary to the respective antisense strand.
  • an HBV RNAi agent disclosed herein comprises:
  • a sense strand that consists of the nucleobase sequence (5'- 3') UUGCCUGUAGGCAUAAAUUGGUAUT (SEQ ID NO: 275); or
  • a sense strand that consists of the nucleobase sequence (5'->3') UAUAUGCCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 276); or
  • a sense strand that consists of the nucleobase sequence (5' - 3') CUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 278); or d. a sense strand that consists of the nucleobase sequence (5'- 3') CGUGGUGGACUUCUCUCAAUU (SEQ ID NO: 285); or
  • a sense strand that consists of the nucleobase sequence (5'- 3') CGUGGUGGACUUCUCUCAAUA (SEQ ID NO: 289); or
  • a sense strand that consists of the nucleobase sequence (5'- 3') CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292); or
  • a sense strand that consists of the nucleobase sequence (5'->3') GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294); or
  • a sense strand that consists of the nucleobase sequence (5'->3') UCGUGGUGGACUUCUCUCAAUU (SEQ ID NO: 300); or
  • a sense strand that consists of the nucleobase sequence (5'- 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); or
  • m. a sense strand that consists of the nucleobase sequence (5'->3') GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); or
  • GGACUUCUCUCAAUUUUCU (SEQ ID NO: 318); or
  • GGACUUCUCUCAAUUUUCA (SEQ ID NO: 320); or
  • r. a sense strand that consists of the nucleobase sequence (5'- 3') GUGGACUUCUCUCAAUUUUCA (SEQ ID NO: 321); or
  • GGCUGUAGGCAUAAAUUGGU SEQ ID NO: 323; or u. a sense strand that consists of the nucleobase sequence (5'- 3')
  • a sense strand that consists of the nucleobase sequence (5'- 3') GCUGUAGGCAUAAAUUGGA (SEQ ID NO: 325); or
  • a sense strand that consists of the nucleobase sequence (5'- 3') GGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 326); or
  • y a sense strand that consists of the nucleobase sequence (5'->3') CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328); or
  • an antisense strand that comprises the nucleobase sequence (5'- 3') AGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 330); or
  • bb a sense strand that consists of the nucleobase sequence (5'- 3') AGGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 331); or
  • cc a sense strand that consists of the nucleobase sequence (5'- 3')
  • a sense strand that consists of the nucleobase sequence (5'->3') C GGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 333); or
  • a sense strand that consists of the nucleobase sequence (5'- 3') CCCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 334);
  • HBV RNAi agent further comprises an antisense strand at least partially complementary to the respective antisense strand.
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 * -»3 * ) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5'- 3') UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154), and a sense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5'- 3') UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that consists of the nucleobase sequence (5' ⁇ 3') GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154), and a sense strand that consists of the nucleobase sequence (5'- 3') CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292).
  • a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5'- 3'
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5'- 3') UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5'- 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188), and a sense strand that consists of the nucleobase sequence (5'- 3') CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328).
  • a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5'- 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5'->3') UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5'- 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5' 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that consists of the nucleobase sequence (5'- 3') GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294).
  • a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5'- 3'
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5'->3') UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5'- 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5' ⁇ 3') UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that consists of the nucleobase sequence (5'->3') GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307).
  • a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5'-
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differ
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5 ⁇ -»3 ⁇ ) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5*-»3*) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5' ⁇ 3') GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 2: 1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 3: 1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 1 : 1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 4: 1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 5: 1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 1 :2.
  • about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD05070 are administered to a subject in need thereof.
  • about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD05070 are administered to a subject in need thereof.
  • about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof.
  • about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD05070 are administered to a subject in need thereof.
  • between about 0.05 and about 5 mg/kg of AD04872 and between about 0.05 and about 5 mg/kg of AD05070 are administered to a subject in need thereof.
  • about AD04872 and about AD05070 are administered separately (e.g., in separate injections).
  • the respective dose of AD04872 and the respective dose of AD05070 are administered together (e.g., in the same injection). In some embodiments, the respective dose of AD04872 and the respective dose of AD05070 are prepared in a single pharmaceutical composition.
  • disclosed herein are methods of treatment of an HBV infection or prevention of diseases or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04872 and an effective amount of AD04776.
  • the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 2: 1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 3: 1.
  • the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 4: 1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 1 : 1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is 5:1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is 1 :2.
  • about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD04776 are administered to a subject in need thereof.
  • about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD04776 are administered to a subject in need thereof.
  • about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof.
  • about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD04776 are administered to a subject in need thereof.
  • between about 0.05 and about 5 mg/kg of AD04872 and between about 0.05 and about 5 mg/kg of AD04776 are administered to a subject in need thereof.
  • the respective doses of AD04872 and AD04776 are administered separately (e.g., in separate injections). In some embodiments, the respective doses of AD04872 and AD04776 are administered together (e.g., in the same injection). In some embodiments, the respective doses of AD04872 and AD04776 are prepared in a single pharmaceutical composition.
  • disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04872 and an effective amount of AD04982.
  • the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 2: 1.
  • the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 3: 1.
  • the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 4: 1.
  • the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 1 : 1.
  • the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 5: 1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is 1 :2. In some embodiments, about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof.
  • about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof.
  • about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD04982 are administered to a subject in need thereof.
  • about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD04982 are administered to a subject in need thereof.
  • about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof.
  • about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD04982 are administered to a subject in need thereof.
  • between about 0.05 and about 5 mg/kg of AD04872 and between about 0.05 and about 5 mg/kg of AD04982 are administered to a subject in need thereof.
  • the respective doses of AD04872 and AD04982 are administered separately (e.g., in separate injections).
  • the respective doses of AD04872 and AD04982 are administered together (e.g., in the same injection).
  • the respective doses of AD04872 and AD04982 are prepared in a single pharmaceutical composition.
  • disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04580 and an effective amount of AD04585.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 2: 1.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 3: 1.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 4: 1.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 5: 1.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 1 : 1. In some embodiments, the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 1 :2. In some embodiments, about 1 mg/kg (mpk) of AD04580 and about 1 mg/kg of AD04585 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04580 and about 1.5 mg/kg of AD04585 are administered to a subject in need thereof. In some embodiments, between about 0.05 and about 5 mg/kg of AD04580 and between about 0.05 and about 5 mg/kg of AD04585 are administered to a subject in need thereof.
  • an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG37)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG37)s shown as a free acid having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04580 linked to (NAG31)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04585 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG37)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG37)s shown as a free acid having the structure represented by the following:
  • the described HBV RNAi agent(s) are optionally combined with one or more additional (i.e., second, third, etc.) therapeutics.
  • a second therapeutic can be another HBV RNAi agent (e.g., a HBV RNAi agent which targets a different sequence within an HBV genome).
  • An additional therapeutic can also be a small molecule drug, antibody, antibody fragment, and or vaccine.
  • the HBV RNAi agents, with or without the one or more additional therapeutics, can be combined with one or more excipients to form pharmaceutical compositions.
  • the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is a nucleoside inhibitor or nucleotide inhibitor. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic entecavir. tenofovir, tenofovir alafenamide, tenofovir disoproxil, lamivudine, or another antiviral therapeutic, in some embodiments, the described HB V RN Ai agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is an interferon.
  • the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is interferon-alpha. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more HBV additional therapeutics, wherein the additional therapeutic is an HBV vaccine.
  • the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics in a single dosage form (i.e., a cocktail included in a single injection).
  • the described HBV RNAi agent(s) may be administered separately from one or more optional additional therapeutics.
  • the described HBV RNAi agent(s) are administered to a subject in need thereof via subcutaneous injection, and the one or more optional additional therapeutics are administered orally, which together provide for a treatment regimen for diseases and conditions associated with HBV infection.
  • the described HBV RNAi agent(s) are administered to a subject in need thereof via subcutaneous injection, and the one or more optional additional therapeutics are administered via a separate subcutaneous injection.
  • compositions for delivering an HBV RNAi agent to a liver cell in vivo including an HBV RNAi agent conjugated or linked to a targeting group.
  • the targeting group is an asialoglycoprotein receptor ligand.
  • compositions for delivering an HBV RNAi agent to a liver cell in vivo are described, the composition including an HBV RNAi agent linked to an N-acetyl- galactosamine targeting ligand.
  • one or more of the described HBV RNAi agents are administered to a mammal in a pharmaceutically acceptable carrier or diluent.
  • the mammal is a human.
  • Hepatitis B Virus RNAi agent provides methods for therapeutic and or prophylactic treatment of diseases/disorders which are associated with HBV infection.
  • the described HBV RNAi agents mediate RNA interference to inhibit the expression of one or more genes necessary for replication and or pathogenesis of Hepatitis B Virus.
  • HBV RNAi agents may inhibit viral polymerase, core protein, surface antigen, e- antigen and/or the X protein, in a cell, tissue or mammal.
  • HBV RNAi agents can be used to treat HBV infection.
  • HBV RNAi agents can also be used to treat or prevent chronic liver diseases/disorders, inflammations, fibrotic conditions and proliferative disorders, like cancers, associated with HBV infection.
  • the methods further comprise treatment of Hepatitis D Virus (HDV) in the subject.
  • HDV Hepatitis D Virus
  • Such methods comprise administration of HBV RNAi agent to a human being or animal infected with HBV. Further, compositions for delivery of HBV RNAi agents to liver cells in vivo are described.
  • compositions comprising one or more HBV RNAi agents can be administered in a number of ways depending upon whether local or systemic treatment is desired. Administration can be, but is not limited to, intravenous, intraarterial, subcutaneous, intraperitoneal, subdermal (e.g., via an implanted device), and intraparenchymal administration. In some embodiments, the pharmaceutical compositions described herein are administered by subcutaneous injection.
  • HBV RNAi agents and or compositions can be used in methods for therapeutic treatment of HBV infection or disease or conditions caused by HBV infection. Such methods include administration of an HBV RNAi agent as described herein to a subject, e.g., a human or animal subject.
  • oligonucleotide and “polynucleotide” mean a polymer of linked nucleosides each of which can be independently modified or unmodified.
  • RNAi agent or "RNAi trigger” means a composition that contains an RNA or RNA-hke (e.g., chemically modified RNA) oligonucleotide molecule that is capable of degrading or inhibiting translation of messenger RNA (mRNA) transcripts of a target mRNA in a sequence specific manner.
  • RNAi agents may operate through the RNA interference mechanism (i.e., inducing RNA interference through interaction with the RNA interference pathway machinery (RNA-induced silencing complex or RISC) of mammalian cells), or by any alternative mechamsm(s) or pathway(s).
  • RNAi agents While it is believed that RNAi agents, as that term is used herein, operate primarily through the RNA interference mechanism, the disclosed RNAi agents are not bound by or limited to any particular pathway or mechanism of action.
  • RN Ai agents disclosed herein are comprised of a sense strand and an antisense strand, and include, but are not limited to: short interfering RNAs (siRNAs), double-stranded RNAs (dsRNA), micro RNAs (mi R As), short hairpin RNAs (shRNA), and dicer substrates.
  • the antisense strand of the RNAi agents described herein is at least partially complementary to the mRNA being targeted.
  • RNAi agents may be comprised of modified nucleotides and/or one or more non-phosphodiester linkages.
  • the terms “silence,” “reduce,” “inhibit,” “down-regulate,” or “knockdown” when referring to expression of a given gene mean that the expression of the gene, as measured by the level of RNA transcribed from the gene or the level of polypeptide, protein or protein subunit translated from the mRNA in a cell, group of cells, tissue, organ, or subject in which the gene is transcribed, is reduced when the cell, group of cells, tissue, organ, or subject is treated with oiigomeric compounds, such as RNAi agents, described herein as compared to a second cell, group of cells, tissue, organ, or subject that has not or have not been so treated.
  • sequence or "nucleotide sequence” mean a succession or order of nucleobases or nucleotides, described with a succession of letters using standard nomenclature.
  • nucleotide base is a heterocyclic pyrimidine or purine compound, which is a standard constituent of all nucleic acids, and includes the bases that form the nucleotides adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U).
  • a nucleobase may further be modified to include, without limitation, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinaied bases.
  • RNAi agent sense strand or targeted mRNA RNAi agent sense strand or targeted mRNA
  • RNAi agent antisense strand or a single-stranded antisense oligonucleotide means the ability of an oligonucleotide or polynucleotide including the first nucleotide sequence to hybridize (form base pair hydrogen bonds under mammalian physiological conditions (or similar conditions in vitro)) and form a duplex or double helical structure under certain conditions with an oligonucleotide or polynucleotide including the second nucleotide sequence.
  • Complementary sequences include Watson-Crick base pairs or non- Watson-Crick base pairs and include natural or modified nucleotides or nucleotide mimics, at least to the extent that the above hybridization requirements are fulfilled. Sequence identity or complementarity is independent of modification. For example, a and Af are complementary to U (or T) and identical to A for the purposes of determining identity or complementarity.
  • perfect complementary or “fully complementary” means that all (100%) of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide.
  • the contiguous sequence may comprise all or a part of a first or second nucleotide sequence.
  • substantially complementary means that in a hy bridized pair of nucleobase sequences, at least about 85%, but not all, of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide.
  • nucleic acid sequence comprises a sequence that has at least about 85% sequence identity or more, preferably at least 90%, at least 95%, or at least 99%, compared to a reference sequence.
  • Percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window. The percentage is calculated by determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
  • the inventions disclosed herein encompasses nucleotide sequences substantially identical to those disclosed herein, e.g., in Tables 2, 3, and 4.
  • sequences disclosed herein are exactly identical, or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percent identical to those disclosed herein, e.g., in Tables 1, 2, 3 and 4.
  • treat means the methods or steps taken to provide relief from or alleviation of the number, severity, and/or frequency of one or more symptoms of a disease or condition in a subject.
  • the phrase "introducing into a cell,” when referring to an oligomeric compound, means functionally delivering the oligomeric compound into a cell.
  • the phrase “functional delivery,” means that delivering the oligomeric compound to the cell in a manner that enables the oligomeric compound to have the expected biological activity, e.g., sequence-specific inhibition of gene expression.
  • isomers refers to compounds that have identical molecular formulae, but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images are termed “enantiomers,” or sometimes optical isomers. A carbon atom bonded to four non-identical substituents is termed a "chiral center.”
  • each structure disclosed herein is intended to represent all such possible isomers, including their optically pure and racemic forms.
  • the structures disclosed herein are intended to cover mixtures of diastereomers as well as single stereoisomers.
  • the compounds and compositions disclosed herein may have certain atoms (e.g., N, 0, or S atoms) in a protonated or deprotonated state, depending upon the environment in which the compound or composition is placed. Accordingly, as used herein, the structures disclosed herein envisage that certain functional groups, such as, for example, OH, SH, or NH, may be protonated or deprotonated. The disclosure herein is intended to cover the disclosed compounds and compositions regardless of their state of protonation based on the environment (such as pH), as would be readily understood by the person of ordinary skill in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
  • RNAi agents for inhibiting expression of Hepatitis B Virus (referred to herein as HBV RNAi agents or HBV RNAi triggers).
  • HBV RNAi agents for inhibiting expression of Hepatitis B Virus (HBV) (referred to herein as HBV RNAi agents or HBV RNAi triggers).
  • HBV RNAi agents comprises a sense strand and an antisense strand.
  • the sense strand and the antisense strand each can be 16 to 30 nucleotides in length.
  • the sense and antisense strands each can be 17 to 26 nucleotides in length.
  • the sense and antisense strands can be either the same length or they can be different lengths.
  • the sense and antisense strands are each independently 17 to 26 nucleotides in length.
  • the sense and antisense strands are each independently 1 7-21 nucleotides in length. In some embodiments, both the sense and antisense strands are each 21-26 nucleotides in length. In some embodiments, the sense strand is about 19 nucleotides in length while the antisense strand is about 21 nucleotides in length. In some embodiments, the sense strand is about 21 nucleotides in length while the antisense strand is about 23 nucleotides in length. In some embodiments, both the sense and antisense strands are each 26 nucleotides in length.
  • RNAi agent sense and antisense strands are each independently 1 7, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length.
  • a double-stranded RNAi agent has a duplex length of about 16, 17. 18, 19, 20, 21. 22, 23 or 24 nucleotides.
  • This region of perfect or substantial complementarity between the sense strand and the antisense strand is typically 15-25 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length and occurs at or near the 5' end of the antisense strand (e.g., this region may be separated from the 5' end of the antisense strand by 0, 1, 2, 3, or 4 nucleotides that are not perfectly or substantially complementary).
  • the sense strand and antisense strand each contain a core stretch sequence that is 16 to 23 nucleobases in length.
  • An antisense strand core stretch sequence is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a nucleotide sequence (sometimes referred to, e.g., as a target sequence) present in the HBV mRNA target.
  • a sense strand core stretch sequence is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a core stretch sequence in the antisense strand, and thus the sense strand core stretch sequence is perfectly identical or at least about 85% identical to a nucleotide sequence (target sequence) present in the HBV mRNA target.
  • a sense strand core stretch sequence can be the same length as a corresponding antisense core sequence or it can be a different length.
  • the antisense strand core stretch sequence is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • the sense strand core stretch sequence is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • RNAi agent duplexes examples include the nucleotide sequences in Tables 3 and 4, are provided in Table 5.
  • the HBV RNAi agent sense and antisense strands anneal to form a duplex.
  • a sense strand and an antisense strand of an HBV RNAi agent may be partially, substantially, or fully complementary to each other.
  • the sense strand core stretch sequence is at least about 85% complementary or 100% complementary to the antisense core stretch sequence.
  • the sense strand core stretch sequence contains a sequence of at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides that is at least about 85% or 100% complementary to a corresponding 16, 17, 18, 19, 20, or 21 nucleotide sequence of the antisense strand core stretch sequence (i.e., the sense strand and antisense core stretch sequences of an HBV RNAi agent have a region of at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides that is at least 85% base paired or 100% base paired.).
  • the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 2 or Table 3. In some embodiments, the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2 or Table 4.
  • the length of the HBV RNAi agent sense and antisense strands described herein are independently 16 to 30 nucleotides in length. In some embodiments, the sense and antisense strands are independently 17 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are 19-26 nucleotides in length. In some embodiments, the described RNAi agent sense and antisense strands are independently 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length. The sense and antisense strands can be either the same length or they can be different lengths. In some embodiments, a sense strand and an antisense strand are each 26 nucleotides in length.
  • a sense strand is 23 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 22 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 21 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 19 nucleotides in length and an antisense strand is 21 nucleotides in length.
  • the sense strand and/or the antisense strand may optionally and independently contain an additional 1, 2, 3, 4, 5, or 6 nucleotides (extension) at the 3' end, the 5' end, or both the 3' and 5' ends of the core sequences.
  • the antisense strand additional nucleotides may or may not be complementary to the corresponding sequence in an HBV mRNA.
  • the sense strand additional nucleotides, if present, may or may not be identical to the corresponding sequence in an HBV mRNA.
  • the antisense strand additional nucl eotides, if present, may or may not be complementary to the corresponding sense strand's additional nucleotides, if present.
  • an extension comprises 1, 2, 3, 4, 5, or 6 nucleotides at the 5' and/or 3' end of the sense strand core stretch sequence and/or antisense strand core stretch sequence.
  • the extension nucleotides on a sense strand may or may not be complementary to nucleotides, either core stretch sequence nucleotides or extension nucleotides, in the corresponding antisense strand.
  • the extension nucleotides on an antisense strand may or may not be complementary to nucleotides, either core stretch sequence nucleotides or extension nucleotides, in the corresponding sense strand.
  • both the sense strand and the antisense strand of an RNAi agent contain 3' and 5' extensions.
  • an HBV RNAi agent has an antisense strand having a 3' extension and a sense strand having a 5' extension. In some embodiments, an HBV RNAi agent comprises an antisense strand having a 3' extension of 1, 2, 3, 4, 5, or 6 nucleotides in length.
  • an HBV RNAi agent comprises an antisense strand having a 3' extension of 1, 2, or 3 nucleotides in length.
  • one or more of the antisense strand extension nucleotides comprise uracil or thymidine nucleotides or nucleotides which are complementary to a corresponding HBV mRNA sequence.
  • a 3' antisense strand extension includes or consists of, but is not limited to: AUA, UGCUU, CUG, UG, UGCC, CUGCC, CGU, CUU, UGCCUA, CUGCCU, UGCCU, UGAUU, GCCUAU, T, TT, U, UU (each listed 5' to 3').
  • the 3' end of the antisense strand may include additional abasic nucleosides (Ab).
  • Ab or AbAb may be added to the 3' end of the antisense strand.
  • an HBV RNAi agent comprises an antisense strand having a 5' extension of 1, 2, 3, 4, or 5 nucleotides in length. In other embodiments, an HBV RNAi agent comprises an antisense strand having a 5' extension of 1 or 2 nucleotides in length. In some embodiments, one or more of the antisense strand extension nucleotides comprises uracil or thymidine nucleotides or nucleotides which are complementary to a corresponding HBV mRNA sequence. In some embodiments, the 5' antisense strand extension includes or consists of, but is no limited to, UA, TU, U, T, UU, TT, CUC (each listed 5' to 3'). An antisense strand may have any of the 3' extensions described above in combination with any of the 5' antisense strand extensions described, if present.
  • an HBV RNAi agent comprises a sense strand having a 3' extension of 1, 2, 3, 4, or 5 nucleotides in length.
  • one or more of the sense strand extension nucleotides comprises adenosine, uracil, or thymidine nucleotides, AT dinucleotide, or nucleotides which correspond to nucleotides in the HBV mRNA sequence.
  • the 3' sense strand extension includes or consists of, but is not limited to: T, UT, TT, UU, UUT, TTT, or TTTT (each listed 5' to 3').
  • the 3' end of the sense strand may include additional abasic nucleosides.
  • UUAb, UAb, or Ab may be added to the 3' end of the sense strand.
  • the one or more abasic nucleosides added to the 3' end of the sense strand may be inverted (invAb).
  • one or more inverted abasic nucleosides may be inserted between the targeting ligand and the nucleobase sequence of the sense strand of the RNAi agent.
  • an HBV RNAi agent comprises a sense strand having a 5' extension of 1, 2, 3, 4, 5, or 6 nucleotides in length.
  • one or more of the sense strand extension nucleotides comprise uracil or adenosine nucleotides or nucleotides which correspond to nucleotides in the HBV mRNA sequence.
  • the sense strand 5' extension can be, but is not limited to: CA, AUAGGC, AUAGG, AUAG, AUA, A, AA, AC, GCA, GGCA, GGC, UAUCA, UAUC, UCA, UAU, U, UU (each listed 5' to 3').
  • a sense strand may have a 3' extension and/or a 5' extension.
  • the 5' end of the sense strand may include an additional abasic nucleoside (Ab) or nucleosides (AbAb).
  • the one or more abasic nucleosides added to the 5' end of the sense strand may be inverted (invAb).
  • one or more inverted abasic nucleosides may be inserted between the targeting ligand and the nucleobase sequence of the sense strand of the RNAi agent.
  • the inclusion of one or more inverted abasic nucleosides at or near the terminal end or terminal ends of the sense strand of an RNAi agent may allow for enhanced activity or other desired properties of an RNAi agent.
  • an HBV RNAi agent antisense strand includes a nucleotide sequence of any of the sequences in Table 3.
  • an HBV RNAi agent antisense strand includes the sequence of nucleotides 1 - 1 7. 2- 15. 2- 1 7. 1-18, 2-18, 1-19, 2- 1 . 1-20, 2-20. 1 -2 1. 2-2 1. 1 -22, 2-22. 1 -23. 2-23. 1 -24. 2-24. 1 -25. 2-25. 1-26, or 2-26 of any of the sequences in Table 3.
  • an HBV RNAi agent sense strand includes the nucleotide sequence of any of the sequences in Table 4. In some embodiments, an HBV RNAi agent sense strand includes the sequence of nucleotides 1-18, 1-19, 1-20, 1 -21. 1 -22, I -
  • the sense and antisense strands of the RNAi agents described herein contain the same number of nucleotides. In some embodiments, the sense and antisense strands of the RNAi agents described herein contain different numbers of nucleotides. In some embodiments, the sense strand 5' end and the antisense strand 3' end of an RNAi agent form a blunt end. In some embodiments, the sense strand 3' end and the antisense strand 5' end of an RNAi agent form a blunt end. In some embodiments, both ends of an RNAi agent form blunt ends.
  • neither end of an RNAi agent is blunt-ended.
  • a blunt end refers to an end of a double stranded RNAi agent in which the terminal nucleotides of the two annealed strands are complementary (form a complementary base-pair).
  • the sense strand 5' end and the antisense strand 3' end of an RNAi agent form a frayed end.
  • the sense strand 3' end and the antisense strand 5' end of an RNAi agent form a frayed end.
  • both ends of an RNAi agent form a frayed end.
  • neither end of an RNAi agent is a frayed end.
  • a frayed end refers to an end of a double stranded RNAi agent in which the terminal nucleotides of the two annealed strands from a pair (i.e. do not form an overhang) but are not complementary (i.e. form a non-complementary pair).
  • an overhang is a stretch of one or more unpaired nucleotides at the end of one strand of a double stranded RNAi agent.
  • the unpaired nucleotides may be on the sense strand or the antisense strand, creating either 3' or 5' overhangs.
  • the RNAi agent contains: a blunt end and a frayed end, a blunt end and 5' overhang end, a blunt end and a 3' overhang end, a frayed end and a 5' overhang end, a frayed end and a 3' overhang end, two 5' overhang ends, two 3' overhang ends, a 5' overhang end and a 3' overhang end, two frayed ends, or two blunt ends.
  • a nucleotide base is a heterocyclic pyrimidine or purine compound which is a constituent of all nucleic acids and includes adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U).
  • nucleotide can include a modified nucleotide (such as, for example, a nucleotide mimic, abasic site (Ab), or a surrogate replacement moiety).
  • Modified nucleotides when used in various polynucleotide or oligonucleotide constructs, may preserve activity of the compound in cells while at the same time increasing the serum stability of these compounds, and can also minimize the possibility of activating interferon activity in humans upon administering of the polynucleotide or oligonucleotide construct.
  • an HBV RNAi agent is prepared or provided as a salt, mixed salt, or a free-acid. In some embodiments, an HBV RNAi agent is prepared as a sodium salt. Such forms are within the scope of the inventions disclosed herein.
  • an HBV RNAi agent contains one or more modified nucleotides.
  • a "modified nucleotide” is a nucleotide other than a ribonucleotide (2'-hydroxyl nucleotide).
  • at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) of the nucleotides are modified nucleotides.
  • modified nucleotides include, but are not limited to, deoxyribonucleotides, nucleotide mimics, abasic nucleotides (represented herein as Ab), 2'- modified nucleotides. 3' to 3' linkages (inverted) nucleotides (represented herein as invdN, invN, invn, invAb), non-natural base-comprising nucleotides, bridged nucleotides, peptide nucleic acids (PNAs), 2',3'-seco nucleotide mimics (unlocked nucleobase analogues, represented herein as NU A or NUNA), locked nucleotides (represented herein as NLNA or NLNA), 3'-0-methoxy (2' internucleoside linked) nucleotides (represented herein as 3'- OMen), 2'-F-Arabino nucleotides (represented herein as NfANA or MANA), 5'-M
  • 2'-modified nucleotides include, but are not limited to, 2'-0-methyl nucleotides (represented herein as a lower case letter 'n' in a nucleotide sequence), 2'-deoxy-2'-fluoro nucleotides (represented herein as Nf, also represented herein as 2'-fluoro nucleotide), 2'-deoxy nucleotides (represented herein as dN), 2'-methoxy ethyl (2'-0-2-methoxylethyl) nucleotides (represented herein as NM or 2'-MOE), 2'-amino nucleotides, and 2'-alkyl nucleotides.
  • 2'-0-methyl nucleotides represented herein as a lower case letter 'n' in a nucleotide sequence
  • 2'-deoxy-2'-fluoro nucleotides represented herein as Nf, also represented herein as 2'-fluoro nucleot
  • HBV RNAi agent sense strands and antisense strands may be synthesized and/or modified by methods known in the art. Modification at one nucleotide is independent of modification at another nucleotide.
  • Modified nucleobases include synthetic and natural nucleobases, such as 5-substituted pyrimidmes, 6-azapyrimi dines and N-2, N-6 and 0-6 substituted purines, (e.g., 2-aminopropyladenine, 5-propynyluracil, or 5-propynylcytosine), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosme, xanthine, hypoxanthine, 2-aminoadenine, 6-alkyl (e.g., 6-methyl, 6-ethyl, 6-isopropyl, or 6-n-butyl) derivatives of adenine and guanine, 2-alkyl (e.g., 2-methyl, 2-ethyl, 2-isopropyl, or 2-n-butyl ) and other alkyl derivatives of adenine and guanine, 2- thiouracil.
  • nucleobases such as 5-substituted pyrimid
  • 2-thiothymine 2-thiocytosine, 5-halouracil, cytosine, 5-propynyl uracil, 5-propynyl cytosine, 6-azo uracil, 6-azo cytosine, 6-azo thymine, -uracil (pseudouracil), 4-thiouracil, 8- halo, 8-amino, 8-sulfhydiyl, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo (e.g., 5-bromo), 5-trifluoiOinethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine, 7-dea/aadenine.
  • 5-halo e.g., 5-bromo
  • RNAi agent all or substantially all of the nucleotides of an RNAi agent are modified nucleotides.
  • an RNAi agent wherein substantially all of the nucleotides present are modified nucleotides is an RN Ai agent having four or fewer (i.e., 0, 1, 2, 3, or 4) nucleotides in both the sense strand and the antisense strand being ribonucleotides.
  • a sense strand wherein substantially all of the nucleotides present are modified nucleotides is a sense strand having two or fewer (i.e., 0, 1, or 2) nucleotides in the sense strand being ribonucleotides.
  • an antisense sense strand wherein substantially all of the nucleotides present are modified nucleotides is an antisense strand having two or fewer (i.e., 0, 1, or 2) nucleotides in the sense strand being ribonucleotides.
  • one or more nucleotides of an RNAi agent is a ribonucleotide.
  • one or more nucleotides of an HBV RNAi agent are linked by nonstandard linkages or backbones (i.e., modified intemucleoside linkages or modified backbones).
  • a modified intemucleoside linkage is a non-phosphate- containing covalent intemucleoside linkage.
  • Modified intemucleoside linkages or backbones include, but are not limited to, 5'-phosphorothioate groups (represented herein as a lower case "s"), chiral phosphorothioates, thiophosphates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, alkyl phosphonates (e.g., methyl phosphonates or 3'-alkylene phosphonates), chiral phosphonates.
  • phosphinates e.g., 3 '-amino phosphoramidate, aminoalkylphosphoramidates, or thionophosphoramidates
  • thionoalkyl- phosphonates thionoalkylphosphotriesters
  • morpholino linkages boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of boranophosphates, or boranophosphates having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.
  • a modified intemucleoside linkage or backbone lacks a phosphorus atom.
  • Modified intemucleoside linkages lacking a phosphoms atom include, but are not limited to, short chain alkyl or cycloalkyl inter-sugar linkages, mixed heteroatom and alkyl or cycloalkyl inter-sugar linkages, or one or more short chain heteroatomic or heterocyclic inter-sugar linkages.
  • modified intemucleoside backbones include, but are not limited to, siloxane backbones, sulfide backbones, sulfoxide backbones, sulfone backbones, formacetyl and thioformacetyl backbones, methylene formacetyl and thioformacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonate and sulfonamide backbones, amide backbones, and other backbones having mixed N, 0, S, and CH2 components.
  • a sense strand of an HBV RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages
  • an antisense strand of an HBV RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages
  • both the sense strand and the antisense strand independently can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages.
  • a sense strand of an HBV RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages
  • an antisense strand of an HBV RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages
  • both the sense strand and the antisense strand independently can contain 1, 2, 3, or 4 phosphorothioate linkages.
  • an HBV RNAi agent sense strand contains at least two phosphorothioate intemucleoside linkages.
  • the at least two phosphorothioate intemucleoside linkages are between the nucleotides at positions 1-3 from the 3' end of the sense strand.
  • the at least two phosphorothioate intemucleoside linkages are between the nucleotides at positions 1-3, 2-4, 3-5, 4-6, 4-5, or 6-8 from the 5' end of the sense strand.
  • an HBV RNAi agent antisense strand contains four phosphorothioate intemucleoside linkages.
  • the four phosphorothioate intemucleoside linkages are between the nucleotides at positions 1-3 from the 5' end of the sense strand and between the nucleotides at positions 19-21, 20-22, 21-23, 22-24, 23-25, or 24- 26 from the 5' end.
  • an HBV RNAi agent contains at least two phosphorothioate intemucleoside linkages in the sense strand and three or four phosphorothioate intemucleoside linkages in the antisense strand.
  • an HBV RNAi agent contains one or more modified nucleotides and one or more modified intemucleoside linkages. In some embodiments, a 2'-modified nucleoside is combined with modified intemucleoside linkage.
  • the HBV RNAi agents disclosed herein target an HBV gene at or near the positions of the HBV genome shown in the following Table 1.
  • the antisense strand of an HBV RNAi agent disclosed herein includes a core stretch sequence that is fully, substantially, or at least partially complementary to a target HBV 19-mer sequence disclosed in Table 1. Table 1.
  • Example 19-mer HBV cDNA target sequences for HBV RNAi agents (taken from Hepatitis B virus (subtype ADW2), genotype A, complete genome GenBank AM282986.1
  • an HBV RNAi agent includes an antisense strand wherein position 19 of the antisense strand ( 5 - 3 ) is capable of forming a base pair with position 1 of a 19-mer target sequence disclosed in Table 1. In some embodiments, an HBV RNAi agent includes an antisense strand wherein position 1 of the antisense strand (5' -> 3') is capable of forming a base pair with position 19 of the 19-mer target sequence disclosed in Table 1. In some embodiments, an HBV RNAi agent includes an antisense strand wherein position 2 of the antisense strand (5 ' -> 3 ' ) is capable of forming a base pair with position 18 of the 19-mer target sequence disclosed in Table 1.
  • an HBV RNAi agent includes an antisense strand wherein positions 2 through 18 of the antisense strand (5 ' - 3 ' ) are capable of forming base pairs with each of the respective complementary bases located at positions 18 through 2 of the 19-mer target sequence disclosed in Table 1.
  • the HBV RNAi agent sense strands and antisense strands that comprise or consist of the nucleotide sequences in Table 2 can be modified nucleotides or unmodified nucleotides.
  • the HBV RNAi agents having the sense and antisense strand sequences that comprise or consist of the nucleotide sequences in Table 2 are all or substantially all modified nucleotides.
  • the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 2.
  • the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2.
  • Modified HBV RNAi agent antisense strand sequences are provided in Table 3.
  • Modified HBV RNAi agent sense strands are provided in Table 4.
  • each of the nucleotides in each of the unmodified sequences listed in Tables 3 and 4 may be a modified nucleotide.
  • Tfs 2'-fluoro-5'-methyluridine-3'-phosphorothioate
  • dN any 2'-deoxyribonucleotide
  • NuNA 2',3'-seco nucleotide mimics (unlocked nucleobase analogs)
  • NLNA locked nucleotide
  • NfANA 2'-F-Arabino nucleotide
  • AMs 2'-methoxyethyladenosine-3'-phosphorothioate
  • TMs 2'-methoxyethylthymidine-3'-phosphorothioate
  • vpdN vinyl phosphonate deoxyribonucleotide
  • Targeting groups and linking groups include the following, for which their chemical structures are provided below in Table 6: (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), (NAG39)s.
  • the HBV RNAi agents described herein are formed by annealing an antisense strand with a sense strand.
  • a sense strand containing a sequence listed in Table 4 can be hybridized to any antisense strand containing a sequence listed in Table 3, provided the two sequences have a region of at least about 85% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence.
  • the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1. 2. or 3 nucleotides from any of the antisense strand sequences in Table 3. In some embodiments, the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 4.
  • an HBV RNAi agent antisense strand comprises a nucleotide sequence of any of the sequences in Table 3. In some embodiments, an HBV RNAi agent antisense strand comprises the sequence of nucleotides (from 5' end - 3' end) 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, 2-24, 1-25, 2-25, 1-26, or 2-26 of any of the sequences in Table 3.
  • an HBV RNAi agent sense strand comprises the nucleotide sequence of any of the sequences in Table 4. In some embodiments, an HBV RNAi agent sense strand comprises the sequence of nucleotides (from 5 : end 3' end) 1-17, 2-17, 3-17, 4-17, 1-18, 2- 18, 3-18, 4-18, 1-19, 2-19, 3-19, 4-19, 1-20, 2-20, 3-20, 4-20, 1-21, 2-21, 3-21, 4-21, 1-22, 2- 22, 3-22, 4-22, 1-23, 2-23, 3-23, 4-23, 1-24, 2-24, 3-24, 4-24, 1-25, 2-25, 3-25, 4-25, 1-26, 2- 26, 3-26, or 4-26 of any of the sequences in Table 4.
  • the nucleotide at position 1 of the antisense strand can be perfectly complementary to an HBV gene, or can be non- complementary to an HBV gene.
  • the nucleotide at position 1 of the antisense strand is a U, A, or dT.
  • the nucleotide at position 1 of the antisense strand forms an A: U or U: A base pair with the sense strand.
  • an HBV RNAi agent antisense strand comprises the sequence of nucleotides (from 5' end 3' end) 2-18 or 2-19 of any of the antisense strand sequences in Table 3.
  • an HBV RNAi sense strand comprises the sequence of nucleotides (from 5' end - 3' end) 1-17 or 1-18 of any of the sense strand sequences in Table 4.
  • an HBV RNAi agent includes (l) an antisense strand comprising the sequence of nucleotides (from 5' end -> 3' end) 2-18 or 2-19 of any of the antisense strand sequences in Table 3, and (ii) a sense strand comprising the sequence of nucleotides (from 5' end 3' end) 1-17 or 1-18 of any of the sense strand sequences in Table 4.
  • a sense strand containing a sequence listed in Table 4 can be hybridized to any antisense strand containing a sequence listed in Table 3 provided the two sequences have a region of at least about 85% complementarit 7 over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence.
  • an HBV RNAi agent comprises of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent consists of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and/or the antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and antisense strand nucleotide sequences of any of the Duplex ID Nos.
  • an HBV RNAi agent comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group and/or linking group wherein the targeting group and/or linking group is covalently linked to the sense strand or the antisense strand.
  • an HBV RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand/sense strand duplexes of Table 5, and further comprises an asialoglycoprotein receptor ligand targeting group.
  • an HBV RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5, and further comprises a targeting group selected from the group consisting of (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG35)s
  • an HBV RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5.
  • an HBV RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5, and further comprises an asialoglycoprotein receptor ligand targeting group.
  • an HBV RNAi agent comprises any of the duplexes of Table 5.
  • an HBV RNAi agent consists of any of the duplexes of Table 5.
  • an HBV RNAi agent is prepared or provided as a salt, mixed salt, or a free-acid.
  • the RNAi agents described herein upon deliver ⁇ ' to a cell expressing an HBV gene, inhibit or knockdown expression of one or more HBV genes in vivo. Targeting Groups, Linking Groups, and Deliver ⁇ ' Vehicles
  • an HBV RNAi agent is conjugated to one or more non-nucleotide groups including, but not limited to a targeting group, linking group, delivery polymer, or a delivery vehicle.
  • the non-nucleotide group can enhance targeting, delivery or attachment of the RNAi agent. Examples of targeting groups and linking groups are provided in Table 6.
  • the non-nucleotide group can be covalently linked to the 3' and/or 5' end of either the sense strand and/or the antisense strand.
  • an HBV RNAi agent contains a non- nucleotide group linked to the 3' and/or 5' end of the sense strand.
  • a non-nucleotide group is linked to the 5' end of an HBV RNAi agent sense strand.
  • a non- nucleotide group may be linked directly or indirectly to the RNAi agent via a linker/linking group.
  • a non-nucleotide group is linked to the RNAi agent via a labile, cleavable, or reversible bond or linker.
  • a non-nucleotide group enhances the pharmacokinetic or biodistribution properties of an RNAi agent or conjugate to which it is attached to improve cell- or tissue-specific distribution and cell-specific uptake of the conjugate. In some embodiments, a non-nucleotide group enhances endocytosis of the RNAi agent.
  • Targeting groups or targeting moieties enhance the pharmacokinetic or biodistribution properties of a conjugate to which they are attached to improve cell-specific distribution and cell-specific uptake of the conjugate.
  • a targeting group can be monovalent, divalent, trivalent, tetravalent, or have higher valency.
  • Representative targeting groups include, without limitation, compounds with affinity to cell surface molecule, cell receptor ligands, hapten, antibodies, monoclonal antibodies, antibody fragments, and antibody mimics with affinity to cell surface molecules.
  • a targeting group is linked to an RNAi agent using a linker, such as a PEG linker or one, two, or three abasic and/or ribitol (abasic ribose) groups.
  • a targeting group comprises a galactose derivative cluster.
  • the HBV RNAi agents described herein may be synthesized having a reactive group, such as an amine group, at the 5'-terminus. The reactive group may be used to subsequently attach a targeting moiety using methods typical in the art.
  • a targeting group comprises an asialoglycoprotein receptor ligand.
  • an asialoglycoprotein receptor ligand includes or consists of one or more galactose derivatives.
  • galactose derivative includes both galactose and derivatives of galactose having affinity for the asialoglycoprotein receptor that is equal to or greater than that of galactose.
  • Galactose derivatives include, but are not limited to: galactose, galactosamine, N-formylgalactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butanoyl-galactosamine, and N-iso-butanoylgalactos-amine (see for example: Iobst, S.T. and Drickamer, K. J.B.C. 1996, 277, 6686).
  • Galactose derivatives, and clusters of galactose derivatives, that are useful for in vivo targeting of oligonucleotides and other molecules to the liver are known in the art (see, for example, Baenziger and Fiete, 1980, Cell, 22, 611-620; Connolly et al., 1982, J. Biol. Chem, 257, 939-945).
  • Galactose derivatives have been used to target molecules to hepatocvtes in vivo through their binding to the asialoglycoprotein receptor (ASGPr) expressed on the surface of hepatocytes.
  • ASGPr asialoglycoprotein receptor
  • ASGPr ligands Binding of ASGPr ligands to the ASGPr(s) facilitates cell-specific targeting to hepatocytes and endocytosis of the molecule into hepatocytes.
  • ASGPr ligands can be monomeric (e.g., having a single galactose derivative) or multimeric (e.g., having multiple galactose derivatives).
  • the galactose derivative or galactose derivative cluster may be attached to the 3 Or 5' end of the RNAi polynucleotide using methods known in the art.
  • the preparation of targeting groups, such as galactose derivative clusters is described in, for example, U.S. Patent Application Serial Nos. 15/452,324 and 15/452,423, the contents of both of which are incorporated herein in their entirety.
  • a galactose derivative cluster comprises a molecule having two to four terminal galactose derivatives. A terminal galactose derivative is attached to a molecule through its C- 1 carbon.
  • the galactose derivative cluster is a galactose derivative trimer (also referred to as tri-antennary galactose derivative or tri-valent galactose derivative).
  • the galactose derivative cluster comprises N-acetyl-galactosamines.
  • the galactose derivative cluster comprises three N-acetyl-galactosamines.
  • the galactose derivative cluster is a galactose derivative tetramer (also referred to as tetra-antennary galactose derivative or tetra-valent galactose derivative). In some embodiments, the galactose derivative cluster comprises four N-acetyl-galactosamines.
  • a galactose derivative trimer contains three galactose derivatives, each linked to a central branch point.
  • a galactose derivative tetramer contains four galactose derivatives, each linked to a central branch point.
  • the galactose derivatives can be attached to the central branch point through the C-l carbons of the saccharides.
  • the galactose derivatives are linked to the branch point via linkers or spacers.
  • the linker or spacer is a flexible hydrophilic spacer, such as a PEG group (see, for example, U.S. Patent No. 5,885,968; Biessen et al. J. Med. Chem. 1995 Vol.
  • the PEG spacer is a PEG3 spacer.
  • the branch point can be any small molecule which permits attachment of three galactose derivatives and further permits attachment of the branch point to the RNAi agent.
  • An example of branch point group is a di- lysine or di-glutamate. Attachment of the branch point to the RNAi agent can occur through a linker or spacer.
  • the linker or spacer comprises a flexible hydrophilic spacer, such as, but not limited to, a PEG spacer.
  • the linker comprises a rigid linker, such as a cyclic group.
  • a galactose derivative comprises or consists of N-acetyl-galactosamine.
  • the galactose derivative cluster is comprised of a galactose derivative tetramer, which can be, for example, an N-acetyl- galactosamine tetramer.
  • compositions for delivering an HBV RNAi agent to a liver cell in vivo are described.
  • Such pharmaceutical compositions can include, for example, an HBV RNAi agent conjugated to a galactose derivative cluster.
  • the galactose derivative cluster is comprised of a galactose derivative trimer, which can be, for example, an N-acetyl-galactosamine trimer, or galactose derivative tetramer, which can be, for example, an N-acetyl-galactosamine tetramer.
  • Targeting groups include, but are not limited to, (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.
  • Other targeting groups including galactose cluster targeting ligands, are known in the
  • a linking group is conjugated to the RNAi agent.
  • the linking group facilitates covalent linkage of the agent to a targeting group or delivery polymer or delivery vehicle.
  • the linking group can be linked to the 3 ' or the 5' end of the RNAi agent sense strand or antisense strand.
  • the linking group is linked to the RNAi agent sense strand.
  • the linking group is conjugated to the 5' or 3' end of an RNAi agent sense strand.
  • a linking group is conjugated to the 5' end of an RNAi agent sense strand.
  • linking groups include, but are not limited to: reactive groups such a primary amines and alkynes, alkyl groups, abasic nucleosides, ribitol (abasic ribose), and/or PEG groups.
  • a linker or linking group is a connection between two atoms that links one chemical group (such as an RNAi agent) or segment of interest to another chemical group (such as a targeting group or delivery polymer) or segment of interest via one or more covalent bonds.
  • a labile linkage contains a labile bond.
  • a linkage may optionally include a spacer that increases the distance between the two joined atoms. A spacer may further add flexibility and/or length to the linkage.
  • Spacers may include, but are not be limited to, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, aralkyl groups, aralkenyl groups, and aralkynyl groups; each of which can contain one or more heteroatoms, heterocycles, amino acids, nucleotides, and saccharides. Spacer groups are well known in the art and the preceding list is not meant to limit the scope of the description. Any of the HBV RNAi agent nucleotide sequences listed in Tables 3 and 4, whether modified or unmodified, may contain 3' or 5' targeting group and/or linking group.
  • HBV RNAi agent sequences listed in Table 3 and 4 which contain a 3' or 5' targeting group and/or linking group may alternatively contain no 3' or 5' targeting group and/or linking group, or may contain a different 3 Or 5' targeting group and/or linking group including, but not limited to, those depicted in Table 3.
  • Any of the HBV RNAi agent duplexes listed in Table 5, whether modified or unmodified may further comprise a targeting group and/or linking group, including, but not limited to, those depicted in Table 3, and the targeting group or linking group may be attached to the 3 Or 5' terminus of either the sense strand or the antisense strand of the HBV RNAi agent duplex.
  • Table 4 provides several embodiments of HBV RNAi agent sense strands having a targeting group or linking group linked to the 5' or 3' end.
  • NAG comprises an N-acetyl-galactosamine or another ASGPr ligand, as would be understood by a person of ordinary skill in the art to be attached in view of the structures above and description provided herein.
  • NAG in the structures provided in Table 6 is represented by the following structu
  • Each (NAGx) may be attached to an HBV RNAi agent via a phosphate group (as in (NAG25), (NAG30), and ( AG31)), or a phosphorothioate group, (as is (NAG25)s, (NAG29)s, (NAG30)s, (NAG31)s, or (NAG37)s), or another linking group.
  • a delivery vehicle may be used to deliver an RNAi agent to a cell or tissue.
  • a deliv ery vehicle is a compound that improves delivery of the RNAi agent to a cell or tissue.
  • a delivery vehicle can include, or consist of, but is not limited to: a polymer, such as an amphipathic polymer, a membrane active polymer, a peptide, a melittin peptide, a melittin- like peptide (MLP), a lipid, a reversibly modified polymer or peptide, or a reversibly modified membrane active poly amine.
  • the RNAi agents can be combined with lipids, nanoparticles, polymers, liposomes, micelles, DPCs or other delivery systems available in the art.
  • the RNAi agents can also be chemically conjugated to targeting groups, lipids (including, but not limited to cholesterol and cholesteryl derivatives), nanoparticles, polymers, liposomes, micelles, DPCs (see, for example WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, WO 2013/032829, WO 2013/158141, each of which is incorporated herein by reference), or other delivery systems available in the art.
  • the HBV RNAi agents disclosed herein may be prepared as pharmaceutical compositions or formulations.
  • pharmaceutical compositions include at least one HBV RNAi agent. These pharmaceutical compositions are particularly useful in the inhibition of the expression of the target niRNA in a target cell, a group of cells, a tissue, or an organism.
  • the pharmaceutical compositions can be used to treat a subject having a disease or disorder that would benefit from reduction in the level of the target mRNA. or inhibition in expression of the target gene.
  • the pharmaceutical compositions can be used to treat a subject at risk of developing a disease or disorder that would benefit from reduction of the level of the target mRNA or an inhibition in expression the target gene.
  • the method includes administering an HBV RNAi agent linked to a targeting hgand as described herein, to a subj ect to be treated.
  • one or more pharmaceutically acceptable excipients are added to the pharmaceutical compositions including an HBV RNAi agent, thereby forming a pharmaceutical formulation suitable for in vivo delivers to a human.
  • compositions that include an HBV RNAi agent and methods disclosed herein may decrease the level of the target mRNA in a cell, group of cells, group of cells, tissue, or subject, including: administering to the subject a therapeutically effective amount of a herein described HB RNAi agent, thereby inhibiting the expression of a target mRNA in the subject.
  • the described pharmaceutical compositions including an HBV RNAi agent are used for treating or managing clinical presentations associated with HBV infection.
  • a therapeutically or prophylactically effective amount of one or more of pharmaceutical compositions is administered to a subject in need of such treatment, prevention or management.
  • administration of any of the disclosed HBV RNAi agents can be used to decrease the number, severity, and/or frequency of symptoms of a disease in a subject.
  • the described pharmaceutical compositions including an HBV RNAi agent can be used to treat at least one symptom in a subject having a disease or disorder that would benefit from reduction or inhibition in expression of HBV mRNA.
  • the subject is administered a therapeutically effective amount of one or more pharmaceutical compositions including an HBV RNAi agent thereby treating the symptom.
  • the subject is administered a prophylactically effective amount of one or more HBV RNAi agents, thereby preventing the at least one symptom.
  • the route of administration is the path by which an HBV RNAi agent is brought into contact with the body.
  • methods of administering drugs and nucleic acids for treatment of a mammal are well known in the art and can be applied to administration of the compositions described herein.
  • the HBV RNAi agents disclosed herein can be administered via any suitable route in a preparation appropriately tailored to the particular route.
  • compositions can be administered by injection, for example, intravenously, intramuscularly, intracutaneous.)', subcutaneously. intraarticularly, or intraperitoneally. In some embodiments, there herein described pharmaceutical compositions via subcutaneous injection.
  • compositions including an HBV RNAi agent described herein can be delivered to a cell, group of cells, tumor, tissue, or subject using oligonucleotide deliver technologies known in the art.
  • any suitable method recogni/ed in the art for delivering a nucleic acid molecule can be adapted for use with a herein described compositions.
  • delivery can be by local administration, (e.g., direct injection, implantation, or topical administering), systemic administration, or subcutaneous, intravenous, intraperitoneal, or parenteral routes, includin intracranial (e.g.
  • compositions are administered by subcutaneous or intravenous infusion or injection.
  • the herein described pharmaceutical compositions may comprise one or more pharmaceutically acceptable excipients.
  • the pharmaceutical compositions described herein can be formulated for administration to a subject.
  • a pharmaceutical composition or medicament includes a pharmacologically effective amount of at least one of the described therapeutic compounds and one or more pharmaceutically acceptable excipients.
  • Pharmaceutically acceptable excipients are substances other than the Active Pharmaceutical ingredient (API, therapeutic product, e.g., HBV RNAi agent) that are intentionally included in the drug delivery system. Excipients do not exert or are not intended to exert a therapeutic effect at the intended dosage.
  • Excipients may act to a) aid in processing of the drug deliver ⁇ ' system during manufacture, b) protect, support or enhance stability, bioavailability or patient acceptability of the API, c) assist in product identification, and/or d) enhance any other attribute of the overall safety, effectiveness, of delivery of the API during storage or use.
  • a pharmaceutically acceptable excipient may or may not be an inert substance.
  • Excipients include, but are not limited to: absorption enhancers, anti-adherents, anti-foaming agents, anti-oxidants, binders, buffering agents, carriers, coating agents, colors, deliver enhancers, delivery polymers, dextran, dextrose, diluents, disintegrants, emulsifiers, extenders, fillers, flavors, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickening agents, tonicity agents, vehicles, water-repelling agents, and wetting agents.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization.
  • dispersions are prepared by- incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the drug that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension.
  • Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic administration.
  • the active compounds can be prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
  • the HBV RNAi agents can be formulated in compositions in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • a pharmaceutical composition can contain other additional components commonly found in pharmaceutical compositions.
  • additional components include, but are not limited to: antipruritics, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamine, diphenhydramine, etc.).
  • anti-inflammatory agents e.g., antihistamine, diphenhydramine, etc.
  • cells, tissues or isolated organs that express or comprise the herein defined RNAi agents may be used as "pharmaceutical compositions.”
  • pharmaceutically effective amount refers to that amount of an RNAi agent to produce a pharmacological, therapeutic or preventive result.
  • an effective amount of an active compound will be in the range of from about 0.1 to about 100 mg/kg of body weight/day, e.g., from about 1.0 to about 50 mg/kg of body weight/day. In some embodiments, an effective amount of an active compound will be in the range of from about 0.25 to about 5 mg/kg of body weight per dose. In some embodiments, an effective amount of an active ingredient will be in the range of from about 0.5 to about 3 mg/kg of body weight per dose.
  • the amount administered will also likely depend on such variables as the overall health status of the patient, the relative biological efficacy of the compound delivered, the formulation of the drug, the presence and types of excipients in the formulation, and the route of administration. Also, it is to be understood that the initial dosage administered can be increased beyond the above upper level in order to rapidly achieve the desired blood-level or tissue level, or the initial dosage can be smaller than the optimum.
  • compositions described herein including an HBV RNAi agent can be combined with an excipient or with a second therapeutic agent or treatment including, but not limited to: a second or other RNAi agent, a small molecule drug, an antibody, an antibody- fragment, and/or a vaccine.
  • the described HBV RNAi agents when added to pharmaceutically acceptable excipients or adjuvants, can be packaged into kits, containers, packs, or dispensers.
  • the pharmaceutical compositions described herein may be packaged in pre- 1 1 led syringes or vials.
  • the HBV RNAi agents disclosed herein can be used to treat a subject (e.g., a human or mammal) having a disease or disorder that would benefit from administration of the compound.
  • the RNAi agents disclosed herein can be used to treat a subject (e.g., a human) having a disease or disorder that would benefit from reduction or inhibition in expression of HBV mRNA.
  • the subject is administered a therapeutically effective amount of any one or more RNAi agents.
  • the subject can be a human, patient, or human patient.
  • the subject may be an adult adolescent, child, or infant.
  • the described pharmaceutical compositions including an HBV RNAi agent can be used to provide methods for the therapeutic treatment of diseases. Such methods include administration of a pharmaceutical composition described herein to a human being or animal.
  • the HBV RNAi agents described herein are used to treat a subject infected with HBV.
  • the described HBV RNAi agents are used to treat at least one symptom in a subject having a HBV infection.
  • the subject is administered a therapeutically effective amount of any one or more of the described RNAi agents.
  • the subject has both a HBV infection and a HDV infection.
  • the HBV RNAi agents described herein are used to treat a subject infected with both HBV and HDV.
  • the described HBV RNAi agents are used to treat at least one symptom in a subject having a HBV or a HDV infection.
  • the subject is administered a therapeutically effective amount of any one or more of the described RNAi agents.
  • the HBV RNAi agents are used to treat or manage a clinical presentation wherein a subject infected with HBV.
  • the subject is administered a therapeutically or effective amount of one or more of the HBV RNAi agents or HBV RNAi agent-containing compositions described herein.
  • the method comprises administering a composition comprising an HBV RNAi agent described herein to a subject to be treated.
  • the gene expression level and/or mRNA level of an HBV gene in a subject to whom a described HBV RNAi agent is administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject pnor to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • the gene expression level and/or mRNA level in the subject may be reduced in a cell, group of cells, and/or tissue of the subject.
  • the expressed protein level of an HBV gene in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • the protein level in the subject may be reduced in a cell, group of cells, tissue, blood, and/or other fluid of the subject.
  • the amount or level of Hepatitis B surface antigen (HBsAg) in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • the amount or level of Hepatitis B e-antigen (HBeAg) in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subj ect prior to being administered the HBV RNAi agent or to a subj ect not receiving the HBV RNAi agent.
  • the amount or level of serum HBV DNA in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • a reduction in the presence of serum HBV DNA, HBV gene expression, HBV mRNA, or HBV protein amounts or levels may be assessed by methods known in the art. Reduction or decrease in HBV mRNA amount or level, expressed protein amount or level, and/or serum HBV DNA amount or level, are collectively referred to herein as a reduction or decrease in HBV or inhibiting or reducing the expression of HBV.
  • Cells, tissues, and non-human organisms that include at least one of the HBV RNAi agents described herein is contemplated.
  • the cell, tissue, or non-human organism is made by delivering the RNAi agent to the cell, tissue, or non-human organism.
  • HBV RNAi agent duplexes shown in Table 5 were synthesized in accordance with the following:
  • a MerMade96E® Bioautomation
  • a MerMadel2® Bioautomation
  • an OP Pilot 100 GE Healthcare
  • Syntheses were performed on a solid support made of controlled pore glass (CPG, 500 A or 600 A, obtained from Prime Synthesis, Aston, PA, USA). All RNA and 2'-modified phosphoramidites were purchased from Thermo Fisher Scientific (Milwaukee, WI, USA).
  • the 2'-deoxy-2'-fluoro-phosphoramidites carried the same protecting groups as the 2'-0-methyl amidites.
  • the abasic (3'-0- dimethoxytrityl-2'-deoxyribose-5' -(2-cyanoethyl-N,N-diisopropylarnino) phosphoramidites were purchased from ChemGenes (Wilmington, MA, USA).
  • Targeting ligand containing phosphoramidites were dissolved in anhydrous dichloromethane or anhydrous acetonitrile (50 mM), while all other amidites were dissolved in anhydrous acetonitrile (50 mM) and molecular sieves (3 A) were added.
  • RNAi agents Some RNAi agents were lyophilized and stored at -15 to -25°C. Duplex concentration was determined by measuring the solution absorbance on aUV-Vis spectrometer in 1 x Phosphate-Buffered Saline. The solution absorbance at 260 nm was then multiplied by a conversion factor and the dilution factor to determine the duplex concentration. Unless otherwise stated, all conversion factor was 0.037 mg/(mL-cm). For some experiments, a conversion factor was calculated from an experimentally determined extinction coefficient.
  • NOD-SCID mice Six to eight-week-old female NOD.CB17-Prkdscid/NcrCrl (NOD-SCID) mice were transiently transfected in vivo with MC-HBV1.3 by hydrodynamic tail vein injection (Yang PL et al. "Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection," PNAS USA 2002 Vol. 99: p. 13825-13830), administered 30 to 45 days prior to administration of an HBV RNAi agent or control.
  • MC-HBV1.3 is a plasmid-derived mini circle that contains the same terminally redundant human hepatitis B virus sequence HBV1.3 as in plasmid pHBV1.3 and in the HBV1.3.32 transgenic mice (GenBank accession #V01460) (Guidotti LG et al, "High-level hepatitis B virus replication in transgenic mice," J Virol 1995 Vol. 69, p6158-6169.). 5 or 10 ⁇ g MC-HBV1.3 in Ringer's Solution in a total volume of 10% of the animal's body weight was injected into mice via tail vein to create pHBV model of chronic HBV infection.
  • HBV RNAi agents At various times, before and after administration of HBV RNAi agents, serum HBsAg, serum HBeAg, serum HBV DNA, or liver HBV RNA may be measured. HBV expression levels were normalized to pre-administration expression levels and to control mice injected with phosphate buffered saline ("PBS").
  • PBS phosphate buffered saline
  • Serum collection Mice were anesthetized with 2-3% isofiurane and blood samples were collected from the submandibular area into serum separation tubes (Sarstedt AG & Co.,
  • HBsAg levels Serum Hepatitis B surface antigen (HBsAg) levels: Serum was collected and diluted 10 to 8000-fold in PBS containing 5% nonfat dry milk. Secondary HBsAg standards diluted in the nonfat milk solution were prepared from serum of ICR mice (Harlan Sprague Dawley) that had been transfected with 10 ⁇ g HBs Ag-expressing plasmid pRc/CMV-HBs (Aldevron, Fargo, ND). HBsAg levels were determined with a GS HBsAg EIA 3.0 kit (Bio-Rad Laboratories, Inc., Redmond, WA) as described by the manufacturer. Recombinant HBsAg protein, ayw subtype, also diluted in nonfat milk in PBS, was used as a primary standard (Aldevron).
  • HBsAg expression for each animal was normalized to the control group of mice injected with PBS in order to account for the non-treatment related decline in expression of MC-HBV1.3.
  • the HBsAg level for each animal at a time point was divided by the pre- treatment level of expression in that animal in order to determine the ratio of expression "normalized to pre-treatment”.
  • Expression at a specific time point was then normalized to the control group by dividing the "normalized to pre-treatment" ratio for an individual animal by the average "normalized to pre-treatment" ratio of all mice in the normal PBS control group.
  • HBeAg analysis was performed with the HBeAg enzyme linked immunosorbent assay (ELISA) as described by the manufacturer (DiaSorin) using serum diluted 4- to 20-fold in 5% nonfat dry milk. The amount of antigen was determined in the linear range of the assay and quantitated against HBeAg protein standards (Fitzgerald Industries International, catalog # 30-AH18, Acton, MA).
  • HBeAg expression for each animal was normalized to the control group of mice injected with PBS in order to account for the non-treatment related decline in expression of MC-HBV1.3.
  • HBeAg is analyzed from pooled group or subgroup serum samples. First, the HBeAg level for each pooled group or subgroup was divided by the pre-treatment level of expression in the same group or subgroup in order to determine the ratio of expression "normalized to pre-treatment". Expression at a specific time point was then normalized to the control group by dividing the "normalized to pre-treatment" ratio for a group or subgroup by the average "normalized to pre-treatment" ratio of all samples from the normal PBS control group.
  • Serum HBVDNA levels Equal volumes of serum from mice in a group or subgroup were pooled to a final volume of 100 ⁇ . DNA was isolated from serum samples using the QIAamp MinElute Virus Spin Kit (Qiagen, Valencia, CA) following the manufacturer's instructions. Sterile 0.9% saline was added to each sample to a final volume of 200 ⁇ . Serum samples were added to tubes containing buffer and protease. Carrier RNA was added to aid in the isolation of small amounts of DNA. 1 ng of pHCR/UbC-SEAP plasmid DNA (Wooddell CI, et al.
  • the number of copies of HBV genomes in DNA isolated from the pHBV mouse model serum was determined by qPCR. Plasmid pSEAP-HBV353-777, encoding a short segment of the HBV genome within the S gene (bases 353-777 of GenBank accession #V01460), was used to create a six log standard curve. Samples with recovery of DNA below 2 standard deviations from the average, based on detection of pHCR'UbC-SEAP were omitted. TaqMan chemistry- based primers and probes with fluor/ZEN/IBFQ are utilized. qPCR assays were performed on a 7500 Fast or StepOne Plus Real-Time PCR system (Life Technologies).
  • HBV DNA was isolated from singlet or duplicate purification steps from pooled group serum samples. Quantitations of HBV DNA and recovery control plasmid were determined by qPCR reactions performed in triplicate. The probes to quantitate HBV and pHCR/UbC-SEAP were included in each reaction.
  • PBS phosphate buffered saline
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • the HBV RNAi agents tested included those having the duplex numbers shown in Table 7, below.
  • RNAi agents AD04178, AD04579, AD04580, AD04570, AD04572, AD04573, AD04574, AD04575, AD04419, and AD04578 were each designed to have antisense strand sequences at least partially complementary to the X open reading frame at positions 1781-1789 of the HBV genome shown in Tables 1 and 2, above.
  • Each of the HBV RNAi agents showed substantial reduction in HBsAg as compared to the PBS control across all measured time points.
  • AD04580 showed greater than 95% reduction in s-antigen levels at day 8 (0.048 ⁇ 0.007 HBsAg level) when normalized to pre-treatment and PBS control.
  • serum HBV DNA levels were determined for the PBS, AD04579, and AD04580 groups from serum samples collected on days 8, 15, 22, 29, 36, 43 and 50, pursuant to the procedure set forth in Example 2, above. Serum from each group was pooled and then DNA was isolated from the serum in duplicate isolations. Data are presented in the following Table: Table 8. Average Serum HBV DNA levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 3 (standard deviation reflected as (+/-)).
  • Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • the HBV RNAi agents administered included those listed in Table 9, below.
  • Table 9 Average HBsAg levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 4 (standard deviation reflected as (+/-)).
  • RNAi agents AD04010, AD04581, AD04591, AD04434, AD04583, AD04584, AD04585, AD04586, AD04588, and AD04438 were designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2.
  • AD04585 exhibited approximately a 90% reduction of HBsAg at day 8, a 95% reduction at day 15, a 97% reduction at day 22, and a 95% reduction at day 29.
  • Table 10 Average Serum HBV DNA levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 4 (standard deviation reflected as (+/-)).
  • HBV RNAi agent AD04585 provided a reduction i DNA levels compared to the PBS group.
  • Example 5 Dose response and combinations of HBV RNAi Agents in pHBV model mice.
  • mice were divided into various groups including those set forth in Table 11, below, and the mice were given 200 ⁇ subcutaneous injections pursuant to the dosing regimen set forth in Table 11 :
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 11.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • HBsAg serum Hepatitis B surface antigen
  • HBV RNAi agents AD04580 and AD04585 each individually showed a reduction in HBsAg as compared to the PBS control across all measured time points. Furthermore, combination treatment of AD04585 and AD04580, which as noted in the Examples above target different regions of the HBV genome, also showed reduction in HBsAg as compared to the PBS control across all measured time points.
  • RNAi agents examined both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group. Re-dosing or increasing the dose amount yielded additional HBV DNA reductions.
  • Example 6 HBV RNAi agents in pHBV mice: dose response and combination studies.
  • mice were divided into various groups as set forth in Table 14, below, and each mouse was administered a single 200 ⁇ subcutaneous injection pursuant to the dosing regimen set forth in Table 14:
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 14.
  • HBV RNAi agents included N-acety 1-galactosamine targeting ligands conj ugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • the HBV RNAi agents tested showed a reduction in HBsAg as compared to the PBS control across all measured time points.
  • combination treatment of AD04872 which includes an antisense strand sequence that is at least partially complementary to the S ORF at positions 261-279 of the HBV genome, as shown in Tables 1 and 2) and either AD04981 or AD04963 (both of which include antisense strand sequences that are at least partially complementary to the X ORF at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2), which are shown in Groups H, I, and J of Example 6, illustrate that combination treatment of two RNAi agents targeting, one which targets in the S ORF, and the other which targets in the X ORF of the HBV genome, similarly showed reduction in HBsAg compared to the PBS control across all measured time points.
  • Serum Hepatitis B e-antigen (HBeAg) levels were also assessed. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • Table 16 Average HBeAg levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 6.
  • AD04872 which targets the S ORF of the HBV genome
  • AD04981 or AD04963 both of which target the X ORF of the HBV genome
  • Example 7 HBV RNAi Agents in pHBV mice: additional dose response and combination studies.
  • mice were divided into various groups as set forth in Table 17, below, and each mouse was administered a single 200 ⁇ subcutaneous injection pursuant to the dosing regimen set forth in Table 17:
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ul of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 17.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conj ugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • the injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area.
  • Table 18 Average HBsAg levels normalized to pre-treatment (day -1) and PBS control in pHBV mice following administration of HBV RNAi agents from Example 7 (standard deviation reflected as (+/-)).
  • HBV RNAi agents tested showed a reduction in HBsAg as compared to the PBS control across all measured time points.
  • Serum Hepatitis B e-antigen (HBeAg) levels were also assessed. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • Table 19 Average HBeAg levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 7.
  • Table 19-1 Average HBeAg fold knockdown normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 7.
  • Table 19-1 reflects the fold knockdown ratio of HBeAg compared to control, which is calculated as normalized HBeAg level of the control (PBS) group/normalized HBeAg level of the respected RNAi agent(s) group (i.e., 1.000/HBeAg level).
  • Serum HBV DNA levels were determined for each of the groups in Table 17 from serum samples collected on days -1, 8, 15, 22, 29, and 36, pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated from each animal at each time point. Data are presented in the following Table: Table 20. Average Serum HBV DNA levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 7 (standard deviation reflected as (+/-)).
  • RNAi agents examined both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group, and further show that the combination of AD04872 (which targets the S ORF) and AD04982 (which targets the X ORF) reduces serum HBV DNA to a similar degree as an equal amount of AD04872 alone.
  • Example 8 HBV RNAi Agents in pHBV mice: further dose response and combination studies.
  • Example 2 The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 21, below, and each mouse was administered a single 200 ⁇ subcutaneous injection pursuant to the dosing regimen set forth in Table 21 : Table 21. Dosing groups of pHBV mice for Example 8.
  • mice are scheduled to be euthanized pursuant to the following schedule:
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 21.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • the injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area.
  • Table 22 Average HBsAg levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 8 (standard deviation reflected as (+/-)).
  • RNAi agent delivery The HBV RNAi agents tested, both alone and in combination, showed a substantial reduction in HBsAg as compared to the PBS control across all measured time points.
  • the HBV RNAi agents tested included those having the duplex numbers shown in Table 23, below, which each included N-acetyl- galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • Table 23 Average HBsAg levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 9 (standard deviation reflected as ( ⁇ /-)).
  • Example 10 HBV RNAi Agents in pHBV mice: further combination studies.
  • mice were divided into various groups as set forth in Table 24, below, and each mouse was administered a single 200 ⁇ subcutaneous injection pursuant to the dosing regimen set forth in Table 24:
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • Serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following:
  • Table 25 Average HBsAg levels normalized to pre-treatment and PBS control (Group A used as control) in pHBV mice following administration of HBV RNAi agents from Example 10
  • HBV RNAi agents AD04585 and AD04771 were designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2.
  • HBV RNAi agents AD04580 and AD04776 were designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2
  • the HBV RNAi agents tested, both alone and in combination, showed a reduction in HBsAg as compared to the PBS control across all measured time points. Each subsequent dose further reduced the nadir of HBsAg reduction.
  • serum HBV DNA levels were determined for Group C (3.0 mg/kg AD04585), Group E (3.0 mg/kg AD04580), and Group G (1.5 mg/kg AD04585 + 1.5 mg/kg AD04580) in Table 24, from serum samples collected on days -1, 8, 15, 22, 29, and 36, 43 and 50 pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated for each animal at each of these time points. Data are presented in the following Table:
  • Table 26 Average Serum HBV DNA levels normalized to pre-treatment and PBS controls (both PBS groups A and B) in pHBV mice following administration of HBV RNAi agents from Example 10 (standard deviation reflected as (+/-)).
  • HBV RNAi Agents in pHBV mice combination studies.
  • mice were divided into various groups as set forth in Table 27, below, and each mouse was administered a single 200 ⁇ subcutaneous injection pursuant to the dosing regimen set forth in Table 27:
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • Serum was collected on day -1 prior to administration, and then on day 8, day 15, day 22, day 29, and day 36 (except for Group L (AD04882) and Group M (AD04885), and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • Table 28 Average HBsAg normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 11 (standard deviation reflected as (+/-)).
  • RNAi agent AD04962 was designed to have an antisense strand sequence that is at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2.
  • RNAi agent AD04872 was designed to have an antisense strand sequence that is at least partially complementary to the S open reading frame at positions 261- 279 of the HBV genome, as shown in Tables 1 and 2.
  • RNAi agent AD04963 was designed to have an antisense strand sequence that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2.
  • RNAi agents AD04882 and AD04885 were designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1780-1798 of the HBV genome, as shown in Tables 1 and 2.
  • Serum Hepatitis B e-antigen (HBeAg) levels were also assessed for all groups except Groups L and M. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • Table 29 Average HBeAg levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 11.
  • serum HBV DNA levels were determined for each of the groups in Table 27 from serum samples collected on days 8, 15, 22, and 29, pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated from each animal at each time point. Data are presented in the following Table: Table 30. Average Serum HBV DNA levels normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 7 (standard deviation reflected as (+/-)).
  • mice were divided into various groups as set forth in Table 31, below, and each mouse was administered a single 200 ⁇ subcutaneous injection pursuant to the dosing regimen set forth in Table 31 :
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • Group A PBS
  • Group B 2.0 mg/kg AD04871
  • Group C 2.0 mg/kg AD04872)
  • Group D 2.0 mg/kg AD04874)
  • Group E 2.0 mg/kg AD04875
  • Group F 2.0 mg/kg AD04876
  • serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • Table 32 Average HBsAg normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 12 (standard deviation reflected as (+/-)).
  • HBV RNAi agents AD04871, AD04872, AD04874, AD04875, and AD04876 were each designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 261-279 of the HBV genome, as shown in Tables 1 and 2.
  • Each of these HBV RNAi agents should a substantial reduction in HBsAg compared to PBS control.
  • a single 2 mg/kg dose of each of AD04871 (Group B), AD04872 (Group C) and AD04874 (Group D), and AD04876 (Group F) exhibited a greater than 90% reduction in HBsAg for each of the timepoints measured from day 15 through day 43 compared to control.
  • HBV RNAi agents AD04881, AD04883, AD04884 were each designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1780-1798 of the HBV genome, as shown in Tables 1 and 2.
  • Example 13 Dose response and combinations of HBV RNAi Agents in X Region Knockout model mice.
  • RNAi agent that includes an antisense strand sequence that is at least partially complementary to a region located in the S ORF of an HBV mRNA
  • a second RNAi agent that includes an antisense strand sequence that is at least partially complementary to a region located in the X ORF of an HBV mRNA
  • a plasmid was generated that included the HBV genome with a knockout of the binding site for HBV RNAi agents that target positions 1780 and 1781, as shown in Tables 1 and 2 (hereinafter referred to as X Region Knockout mice). This model was generated by mutating ten (10) bases in the pHBV1.3 plasmid within the binding site of these RNAi agents.
  • HBV RNAi agent having an antisense strand that targets positions 1780 and 1781 of the HBV genome disclosed herein is expected to be ineffective in silencing expression.
  • mice were divided into various groups including those set forth in Table 33, below, and the mice were given 200 ⁇ subcutaneous injections pursuant to the dosing regimen set forth in the following Table: Table 33.
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 33.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • Table 34 Average HBsAg normalized to pre-treatment and PBS control in X Region Knockout mice following administration of HBV RNAi agents from Example 13 (standard deviation reflected as (+/-)).
  • Group 6 which was a single dose of 3.0 mg/kg of HBV RNAi agent AD04963 and includes an antisense strand that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, was unable to provide knockdown of HBsAg. Additionally, each of Groups 2 through 5 provided substantial knockdown of HBsAg compared to PBS control, with both Group 3 and Group 5 exhibiting a greater than 2 log reduction in HBsAg at nadir (day 22).
  • Example 14 Dose response and combinations of HBV RNAi Agents in X Region Knockout model mice.
  • mice were divided into various groups including those set forth in Table 31, below, and each mouse was administered a single 200 ⁇ subcutaneous injection pursuant to the dosing regimen set forth in Table 35:
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 35.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • the injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area.
  • HBsAg serum Hepatitis B surface antigen
  • Table 36 shows that HBV RNAi agent AD04872 administered alone, and the combination of AD04872 (which includes an antisense strand that is at least partially complementary to the S open reading from at positions 261-279 of the HBV genome) and AD05070 (which includes an antisense strand that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome), provided significant knockdown of HBsAg compared to PBS control across each of the time points measured. .
  • Addition of 0.7 mg/kg to 2 mg/kg HBV RNAi agent AD05070 for which there was a mutated target site in this X Region Knockout model did not diminish the activity of the 2 mg/kg HBV RNAi agent AD04872.
  • serum HBV DNA levels were determined from serum samples collected on days 8, 15, and 22 pursuant to the procedure set forth in Example 2, above. Serum from each group was pooled and then DNA was isolated from the serum in singlet. Data are presented in the following Table: Table 37. Average Serum HBV DNA levels normalized to pre-treatment and PBS controls in X Region Knockout mice following administration of HBV RNAi agents from Example 14 (standard deviation reflected as (+/-)).
  • Example 15 HBV RNAi agents in pHBV mice.
  • mice were divided into various groups including those set forth in Table 38, below, and each mouse was administered a single 200 ⁇ subcutaneous injection pursuant to the dosing regimen set forth in Table 38:
  • Each mouse was given a subcutaneous administration of 200 ⁇ containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 38.
  • HBV RNAi agents included N-acety 1-galactosamine targeting ligands conj ugated to the 5 ' -terminal end of the sense strand, as shown in Tables 4 and 5.
  • Serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table 39, with Average HBsAg reflecting the normalized average value of HBsAg:
  • Table 39 Average HBsAg normalized to pre-treatment and PBS control in pHBV mice following administration of HBV RNAi agents from Example 15.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/US2017/045446 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION Ceased WO2018027106A2 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
IL305507A IL305507A (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
CR20220468A CR20220468A (es) 2016-08-04 2017-08-04 AGENTES DE iARN PARA INFECCION CAUSADA POR EL VIRUS DE LA HEPATITIS B (Divisional 2019-0056)
MX2019001493A MX2019001493A (es) 2016-08-04 2017-08-04 Agentes de iarn para infección causada por el virus de la hepatitis b.
KR1020197006273A KR102500675B1 (ko) 2016-08-04 2017-08-04 B형 간염 바이러스 감염에 대한 RNAi 작용제
PE2023003074A PE20250393A1 (es) 2016-08-04 2017-08-04 AGENTES DE iARN PARA INFECCION CAUSADA POR EL VIRUS DE LA HEPATITIS B
KR1020237005107A KR102540359B1 (ko) 2016-08-04 2017-08-04 B형 간염 바이러스 감염에 대한 RNAi 작용제
BR112019002117-5A BR112019002117A2 (pt) 2016-08-04 2017-08-04 agente de rnai contra infecção do vírus da hepatite b
IL264575A IL264575B2 (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
CA3032945A CA3032945A1 (en) 2016-08-04 2017-08-04 Rnai agents for hepatitis b virus infection
CR20220469A CR20220469A (es) 2016-08-04 2017-08-04 AGENTES DE iARN PARA INFECCIÓN CAUSADA POR EL VIRUS DE LA HEPATITIS B. (Divisional 2019-0056).
US15/766,036 US10780108B2 (en) 2016-08-04 2017-08-04 RNAi agents for Hepatitis B virus infection
EP17837738.8A EP3494123B1 (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
CR20190056A CR20190056A (es) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
CN201780061911.7A CN109843902B (zh) 2016-08-04 2017-08-04 用于B型肝炎病毒感染的RNAi剂
MYPI2019000637A MY199749A (en) 2016-08-04 2017-08-04 Rnai agents for hepatitis b virus infection
KR1020247009034A KR102774202B1 (ko) 2016-08-04 2017-08-04 B형 간염 바이러스 감염에 대한 RNAi 작용제
ES17837738T ES2988612T3 (es) 2016-08-04 2017-08-04 Agentes de ARNi para la infección por el virus de la hepatitis B
CN202310672003.9A CN116514890A (zh) 2016-08-04 2017-08-04 用于B型肝炎病毒感染的RNAi剂
KR1020237018497A KR102650107B1 (ko) 2016-08-04 2017-08-04 B형 간염 바이러스 감염에 대한 RNAi 작용제
AU2017306692A AU2017306692B2 (en) 2016-08-04 2017-08-04 RNAi agents for Hepatitis B virus infection
EA201990427A EA201990427A1 (ru) 2017-08-03 2017-08-04 АГЕНТЫ РНКи ПРОТИВ ИНФЕКЦИИ, ВЫЗВАННОЙ ВИРУСОМ ГЕПАТИТА В
NZ750390A NZ750390B2 (en) 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
EP24162143.2A EP4364808A3 (en) 2016-08-04 2017-08-04 Rnai agents for hepatitis b virus infection
SG11201900910TA SG11201900910TA (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
JP2019505172A JP7237816B2 (ja) 2016-08-04 2017-08-04 Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
US16/267,194 US20190255091A1 (en) 2016-08-04 2019-02-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
PH12019500245A PH12019500245A1 (en) 2016-08-04 2019-02-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
CONC2019/0002017A CO2019002017A2 (es) 2016-08-04 2019-03-01 Agentes de iarn para infección causada por el virus de la hepatitis b
US16/990,916 US11590156B2 (en) 2016-08-04 2020-08-11 RNAi agents for hepatitis B virus infection
US17/529,107 US11517584B2 (en) 2016-08-04 2021-11-17 RNAi agents for Hepatitis B virus infection
JP2022015856A JP2022068222A (ja) 2016-08-04 2022-02-03 Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
AU2022205929A AU2022205929B2 (en) 2016-08-04 2022-07-18 RNAi agents for Hepatitis B virus infection
US18/074,268 US20230355651A1 (en) 2016-08-04 2022-12-02 Rnai agents for hepatitis b virus infection
JP2023090659A JP7625637B2 (ja) 2016-08-04 2023-06-01 Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
JP2024115530A JP2024150603A (ja) 2016-08-04 2024-07-19 Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
AU2024219418A AU2024219418A1 (en) 2016-08-04 2024-09-05 RNAi agents for Hepatitis B virus infection

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662370754P 2016-08-04 2016-08-04
US62/370,754 2016-08-04
US201762534733P 2017-07-20 2017-07-20
US62/534,733 2017-07-20
US201762540639P 2017-08-03 2017-08-03
US62/540,639 2017-08-03

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/766,036 A-371-Of-International US10780108B2 (en) 2016-08-04 2017-08-04 RNAi agents for Hepatitis B virus infection
US16/267,194 Continuation US20190255091A1 (en) 2016-08-04 2019-02-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
US16/990,916 Continuation US11590156B2 (en) 2016-08-04 2020-08-11 RNAi agents for hepatitis B virus infection

Publications (2)

Publication Number Publication Date
WO2018027106A2 true WO2018027106A2 (en) 2018-02-08
WO2018027106A3 WO2018027106A3 (en) 2018-03-15

Family

ID=61073185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/045446 Ceased WO2018027106A2 (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Country Status (24)

Country Link
US (5) US10780108B2 (cg-RX-API-DMAC7.html)
EP (2) EP4364808A3 (cg-RX-API-DMAC7.html)
JP (4) JP7237816B2 (cg-RX-API-DMAC7.html)
KR (4) KR102540359B1 (cg-RX-API-DMAC7.html)
CN (2) CN116514890A (cg-RX-API-DMAC7.html)
AU (3) AU2017306692B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019002117A2 (cg-RX-API-DMAC7.html)
CA (2) CA3032945A1 (cg-RX-API-DMAC7.html)
CL (4) CL2019000278A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019002017A2 (cg-RX-API-DMAC7.html)
CR (3) CR20220469A (cg-RX-API-DMAC7.html)
EC (1) ECSP19015395A (cg-RX-API-DMAC7.html)
ES (1) ES2988612T3 (cg-RX-API-DMAC7.html)
IL (2) IL264575B2 (cg-RX-API-DMAC7.html)
JO (2) JOP20170161A1 (cg-RX-API-DMAC7.html)
MA (1) MA45863A (cg-RX-API-DMAC7.html)
MX (3) MX2019001493A (cg-RX-API-DMAC7.html)
MY (1) MY199749A (cg-RX-API-DMAC7.html)
PE (2) PE20250393A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019500245A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201913585SA (cg-RX-API-DMAC7.html)
TW (2) TWI840321B (cg-RX-API-DMAC7.html)
UY (2) UY37353A (cg-RX-API-DMAC7.html)
WO (1) WO2018027106A2 (cg-RX-API-DMAC7.html)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020036862A1 (en) * 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2020132346A1 (en) * 2018-12-20 2020-06-25 Vir Biotechnology, Inc. Combination hbv therapy
WO2020163747A1 (en) * 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for hepatitis b virus infection
US10799524B2 (en) 2017-10-20 2020-10-13 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis B infection
US10806750B2 (en) 2015-08-07 2020-10-20 Arrowhead Pharmaceuticals, Inc. RNAi therapy for hepatitis B virus infection
WO2020214976A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2020214974A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
USRE48345E1 (en) 2011-06-30 2020-12-08 Arrowhead Pharmaceuticals Inc. Compositions and methods for inhibiting gene expression of hepatitis B virus
WO2020255008A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
WO2020255007A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
US11180529B2 (en) 2016-11-01 2021-11-23 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof
WO2021263271A1 (en) * 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
WO2022056273A1 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Lipid conjugates for the delivery of therapeutic agents
WO2022063782A1 (en) 2020-09-22 2022-03-31 Astrazeneca Ab Method of treating fatty liver disease
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
WO2022133230A1 (en) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) * 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
US11414665B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
EP3607069B1 (en) 2017-04-05 2022-11-02 Silence Therapeutics GmbH Products and compositions
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
US11517584B2 (en) 2016-08-04 2022-12-06 Arrowhead Pharmaceuticals, Inc. RNAi agents for Hepatitis B virus infection
US20230002767A1 (en) * 2021-05-28 2023-01-05 Arrowhead Pharmaceuticals, Inc. RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
US11597701B2 (en) 2017-11-01 2023-03-07 Arrowhead Pharmaceuticals, Inc. Integrin ligands and uses thereof
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
EP3992291A4 (en) * 2019-06-28 2023-08-02 Kylonova (Xiamen) Biopharma Co., Ltd. Novel compound and application thereof
US11725194B2 (en) 2017-12-19 2023-08-15 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2024015796A1 (en) * 2022-07-11 2024-01-18 Sanegene Bio Usa Inc. Optimized 2'- modified ribose derivatives and methods of use
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
WO2024137543A1 (en) * 2022-12-19 2024-06-27 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar)
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
WO2025242771A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use
US12486502B2 (en) 2021-04-08 2025-12-02 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
US12497622B2 (en) 2019-05-22 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US12496347B2 (en) 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942841A (zh) * 2016-09-02 2023-10-27 箭头药业股份有限公司 靶向配体
US20240033278A9 (en) * 2020-06-10 2024-02-01 Medshine Discovery Inc. Conjugate group and conjugate
WO2022078479A1 (en) * 2020-10-16 2022-04-21 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CN116916935A (zh) * 2020-12-18 2023-10-20 奥利克斯医药有限公司 抑制乙型肝炎病毒表达的RNAi制剂以及其用途
WO2023246750A1 (zh) * 2022-06-21 2023-12-28 正大天晴药业集团股份有限公司 用于抑制乙型肝炎病毒的双链核糖核酸

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
WO2008022309A2 (en) 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
WO2011104169A1 (en) 2010-02-24 2011-09-01 F. Hoffmann-La Roche Ag Compositions for targeted delivery of sirna
WO2012083185A2 (en) 2010-12-17 2012-06-21 Arrowhead Research Corporations Peptide-based in vivo sirna delivery system
US20130005793A1 (en) 2011-06-30 2013-01-03 Arrowhead Research Corporation Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
WO2013158141A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
WO2015050871A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compounds to treat hepatitis b virus
WO2016077349A1 (en) 2014-11-10 2016-05-19 Alnylam Pharmaceuticals, Inc. HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20160152973A1 (en) 2001-05-18 2016-06-02 Sirna Therapeutics, Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
CA1340032C (en) 1987-06-24 1998-09-08 Jim Haralambidis Lucleoside derivatives
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
JPH05504552A (ja) 1989-10-24 1993-07-15 ギリアド　サイエンシズ，インコーポレイテッド ２’位が改変されたオリゴヌクレオチド
EP0800830A3 (en) 1989-11-03 1999-03-17 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
WO1993007883A1 (en) 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5321131A (en) * 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5359044A (en) * 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
EP0691977B1 (en) 1993-03-31 1997-11-26 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5856459A (en) 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
AU6430599A (en) 1998-10-09 2000-05-01 Cytogenix, Inc. Enzymatic synthesis of ssdna
US5977341A (en) 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
DK1102785T3 (da) 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
US7019113B2 (en) 1999-06-07 2006-03-28 Mirus Bio Corporation Reversible modification of membrane interaction
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
JP2004532022A (ja) 2001-03-26 2004-10-21 サーナ・セラピューティクス・インコーポレイテッド Ｂ型肝炎ウイルスおよびｃ型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
AU2004266311B2 (en) 2001-05-18 2009-07-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US6635428B2 (en) 2001-12-04 2003-10-21 Quest Diagnostics Investments Incorporated Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
ATE529512T1 (de) 2002-02-01 2011-11-15 Life Technologies Corp Doppelsträngige oligonukleotide
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
CN1257284C (zh) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
WO2005021751A1 (en) 2003-09-01 2005-03-10 Patrick Arbuthnot A self-processing rna expression cassette
US20080145346A1 (en) 2003-12-16 2008-06-19 Agency For Science, Technology And Research Methods And Compounds For Altering The Load Of Hepatitis Virus
CA2553211A1 (en) 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
US20050277610A1 (en) 2004-03-15 2005-12-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
EP1786905B1 (en) 2004-08-18 2011-08-03 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
KR20100060018A (ko) 2005-03-09 2010-06-04 재단법인 목암생명공학연구소 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
JP2008537551A (ja) 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
CN101426912A (zh) 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
KR20080036650A (ko) 2005-08-17 2008-04-28 시르나 쎄러퓨틱스 인코퍼레이티드 Ｒｎａ 간섭을 매개하는 화학적으로 변형된 짧은 간섭 핵산분자
RU2418068C2 (ru) 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
EP2202239A1 (en) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication
CN100447243C (zh) 2005-11-15 2008-12-31 中国人民解放军第四军医大学 HBV特异性干涉靶位点基因及其siRNA和其在抗HBV感染中的应用
CN101024088A (zh) 2006-02-20 2007-08-29 桂林医学院 抗乙型肝炎病毒微小核糖核酸干扰分子及其设计方法
WO2008119000A1 (en) 2007-03-27 2008-10-02 University Of Iowa Research Foundation Zinc-finger nuclease and rna interference mediated inactivation of viral genomes
WO2008131419A2 (en) 2007-04-23 2008-10-30 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
EP2164965B1 (en) 2007-05-29 2013-09-11 University Of The Witwatersrand, Johannesburg A primary micro rna expression cassette
KR20100069679A (ko) 2007-09-17 2010-06-24 재단법인 목암생명공학연구소 ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법
EP2205740A2 (en) 2007-10-02 2010-07-14 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
CA3044980A1 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
CN101603042B (zh) 2008-06-13 2013-05-01 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
CN103275971A (zh) * 2008-06-13 2013-09-04 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
CN101322847A (zh) 2008-06-23 2008-12-17 淮安市第四人民医院 基于siRNA池干扰的复合载体介导的抗乙肝病毒基因药物
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
CA2761106C (en) 2009-05-05 2019-01-15 Miragen Therapeutics Lipophilic polynucleotide conjugates
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
SG177560A1 (en) 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
EP2390327A1 (en) 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
WO2012037254A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
CN101948834B (zh) 2010-09-16 2012-07-04 山东大学 用于治疗HBV的siRNA
BR112013010525A2 (pt) 2010-10-28 2016-08-02 Benitec Biopharma Ltd tratamento de hbv
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
KR20130108655A (ko) 2010-12-29 2013-10-04 에프. 호프만-라 로슈 아게 핵산의 세포내 전달을 위한 소분자 접합체
KR102055331B1 (ko) * 2011-04-21 2019-12-12 아이오니스 파마수티컬즈, 인코포레이티드 B형 간염 바이러스(hbv) 발현 조절
AU2012258220B2 (en) 2011-05-18 2017-01-19 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
AU2012340159B2 (en) 2011-11-18 2017-09-07 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
US9212363B2 (en) 2012-05-11 2015-12-15 City Of Hope RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
WO2013176772A1 (en) 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN103333890B (zh) * 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 治疗乙型病毒性肝炎的rna干扰制剂
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
EP3137115B1 (en) 2014-05-01 2020-10-14 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
CN104059916A (zh) 2014-06-17 2014-09-24 湖北医药学院附属太和医院 乙肝病毒特异性的microRNA样siRNA序列及其用途
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
CN108136206B (zh) 2015-07-17 2021-10-15 阿克丘勒斯治疗公司 抗乙型肝炎病毒的组合物和药剂及其用途
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
JP7336191B2 (ja) 2015-08-07 2023-08-31 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルス感染に対するＲＮＡｉ療法
US10246709B2 (en) 2016-03-07 2019-04-02 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
MA45478A (fr) 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
CN116942841A (zh) 2016-09-02 2023-10-27 箭头药业股份有限公司 靶向配体
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
AU2020219355A1 (en) 2019-02-07 2021-09-30 Arrowhead Pharmaceuticals, Inc. RNAi agents for Hepatitis B virus infection
WO2020214974A1 (en) 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
SG11202112240VA (en) 2019-05-13 2021-12-30 Vir Biotechnology Inc Compositions and methods for treating hepatitis b virus (hbv) infection
KR20220042116A (ko) 2019-06-18 2022-04-04 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
CA3188801A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US20160152973A1 (en) 2001-05-18 2016-06-02 Sirna Therapeutics, Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
WO2008022309A2 (en) 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
WO2011104169A1 (en) 2010-02-24 2011-09-01 F. Hoffmann-La Roche Ag Compositions for targeted delivery of sirna
WO2012083185A2 (en) 2010-12-17 2012-06-21 Arrowhead Research Corporations Peptide-based in vivo sirna delivery system
US20130005793A1 (en) 2011-06-30 2013-01-03 Arrowhead Research Corporation Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus
WO2013003520A1 (en) 2011-06-30 2013-01-03 Arrowhead Research Corporation Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
WO2013158141A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
WO2015050871A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compounds to treat hepatitis b virus
WO2016077349A1 (en) 2014-11-10 2016-05-19 Alnylam Pharmaceuticals, Inc. HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAENZIGERFIETE, CELL, vol. 22, 1980, pages 611 - 620
CONNOLLY ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 939 - 945
IOBST, S.T.DRICKAMER, K, J.B.C., vol. 271, 1996, pages 6686

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48345E1 (en) 2011-06-30 2020-12-08 Arrowhead Pharmaceuticals Inc. Compositions and methods for inhibiting gene expression of hepatitis B virus
US11534453B2 (en) 2015-08-07 2022-12-27 Arrowhead Pharmaceuticals, Inc. RNAi therapy for hepatitis B virus infection
US10806750B2 (en) 2015-08-07 2020-10-20 Arrowhead Pharmaceuticals, Inc. RNAi therapy for hepatitis B virus infection
US11517584B2 (en) 2016-08-04 2022-12-06 Arrowhead Pharmaceuticals, Inc. RNAi agents for Hepatitis B virus infection
US11590156B2 (en) 2016-08-04 2023-02-28 Arrowhead Pharmaceuticals, Inc. RNAi agents for hepatitis B virus infection
US11180529B2 (en) 2016-11-01 2021-11-23 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof
US12173086B2 (en) 2016-11-01 2024-12-24 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof
EP3607069B1 (en) 2017-04-05 2022-11-02 Silence Therapeutics GmbH Products and compositions
US12084656B2 (en) 2017-04-05 2024-09-10 Silence Therapeutics Gmbh Products and compositions
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US11273173B2 (en) 2017-10-20 2022-03-15 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis B infection
US11052105B2 (en) 2017-10-20 2021-07-06 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis B infection
US11052104B2 (en) 2017-10-20 2021-07-06 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis B infection
US10799524B2 (en) 2017-10-20 2020-10-13 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis B infection
US11597701B2 (en) 2017-11-01 2023-03-07 Arrowhead Pharmaceuticals, Inc. Integrin ligands and uses thereof
US11414665B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US12084661B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
US12274752B2 (en) 2017-12-01 2025-04-15 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
US12428642B2 (en) 2017-12-01 2025-09-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
US11725194B2 (en) 2017-12-19 2023-08-15 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US12173289B2 (en) 2018-08-13 2024-12-24 Alnylam Pharmaceuticals, Inc. Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
US11492623B2 (en) 2018-08-13 2022-11-08 Alnylam Pharmaceuticals, Inc. Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
WO2020036862A1 (en) * 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
IL280559B1 (en) * 2018-08-13 2025-11-01 Alnylam Pharmaceuticals Inc Hepatitis B virus dsRNA preparations and methods of using them
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
EP4285929A3 (en) * 2018-12-20 2024-03-06 Humabs Biomed SA Combination hbv therapy
CN113543791A (zh) * 2018-12-20 2021-10-22 维尔生物科技有限公司 组合hbv疗法
WO2020132346A1 (en) * 2018-12-20 2020-06-25 Vir Biotechnology, Inc. Combination hbv therapy
US12404318B2 (en) 2018-12-20 2025-09-02 Vir Biotechnology, Inc. Combination HBV therapy
US12496347B2 (en) 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2020163747A1 (en) * 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for hepatitis b virus infection
JP2022521155A (ja) * 2019-02-07 2022-04-06 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
TWI872048B (zh) * 2019-02-07 2025-02-11 美商艾羅海德製藥公司 用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑
JP2024153797A (ja) * 2019-02-07 2024-10-29 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
CN113507920A (zh) * 2019-02-07 2021-10-15 箭头药业股份有限公司 用于乙型肝炎病毒感染的RNAi剂
WO2020214976A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CN114072142A (zh) * 2019-04-18 2022-02-18 杨森制药公司 用于治疗乙型肝炎病毒感染的组合疗法
WO2020214974A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
US12497622B2 (en) 2019-05-22 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
JP2022536945A (ja) * 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
WO2020255007A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
WO2020255008A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
EP3992291A4 (en) * 2019-06-28 2023-08-02 Kylonova (Xiamen) Biopharma Co., Ltd. Novel compound and application thereof
JP2023531682A (ja) * 2020-06-22 2023-07-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｄ型肝炎ウイルス感染の処置のための組成物および方法
WO2021263271A1 (en) * 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
WO2022056273A1 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Lipid conjugates for the delivery of therapeutic agents
WO2022063782A1 (en) 2020-09-22 2022-03-31 Astrazeneca Ab Method of treating fatty liver disease
WO2022133230A1 (en) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) * 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
US12486502B2 (en) 2021-04-08 2025-12-02 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
US12365897B2 (en) * 2021-05-28 2025-07-22 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
US20230002767A1 (en) * 2021-05-28 2023-01-05 Arrowhead Pharmaceuticals, Inc. RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2024015796A1 (en) * 2022-07-11 2024-01-18 Sanegene Bio Usa Inc. Optimized 2'- modified ribose derivatives and methods of use
WO2024137543A1 (en) * 2022-12-19 2024-06-27 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar)
WO2025242771A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use
WO2025242321A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use

Also Published As

Publication number Publication date
UY37353A (es) 2018-02-28
CL2020002156A1 (es) 2020-12-18
JP7237816B2 (ja) 2023-03-13
KR102500675B1 (ko) 2023-02-15
MA45863A (fr) 2019-06-12
US20220079973A1 (en) 2022-03-17
MX2019001493A (es) 2019-07-12
BR112019002117A2 (pt) 2019-07-09
US10780108B2 (en) 2020-09-22
CN116514890A (zh) 2023-08-01
WO2018027106A3 (en) 2018-03-15
AU2017306692A1 (en) 2019-02-21
JOP20190015A1 (ar) 2019-02-04
AU2024219418A1 (en) 2024-09-26
CR20190056A (es) 2019-05-20
KR102650107B1 (ko) 2024-03-20
US20190255091A1 (en) 2019-08-22
MX2020011805A (es) 2020-12-07
JP2024150603A (ja) 2024-10-23
PE20250393A1 (es) 2025-02-11
CN109843902A (zh) 2019-06-04
EP3494123A2 (en) 2019-06-12
NZ750390A (en) 2023-11-24
US11517584B2 (en) 2022-12-06
TWI840321B (zh) 2024-05-01
CL2022001478A1 (es) 2023-01-13
TW202334420A (zh) 2023-09-01
CN109843902B (zh) 2023-05-30
KR20240039232A (ko) 2024-03-26
EP3494123C0 (en) 2024-09-25
IL264575B2 (en) 2024-02-01
CR20220468A (es) 2023-05-12
JP2022068222A (ja) 2022-05-09
PH12019500245A1 (en) 2019-10-14
AU2022205929B2 (en) 2024-06-13
CL2019000278A1 (es) 2020-03-20
US20190292547A1 (en) 2019-09-26
US11590156B2 (en) 2023-02-28
JP2019527694A (ja) 2019-10-03
IL305507A (en) 2023-10-01
ES2988612T3 (es) 2024-11-21
EP3494123A4 (en) 2020-07-22
CA3032945A1 (en) 2018-02-08
PE20190567A1 (es) 2019-04-22
CA3229270A1 (en) 2018-02-08
CR20220469A (es) 2022-10-26
TWI868509B (zh) 2025-01-01
SG11201900910TA (en) 2019-02-27
JOP20170161A1 (ar) 2019-01-30
UY40527A (es) 2024-01-15
SG10201913585SA (en) 2020-02-27
TW202018081A (zh) 2020-05-16
KR102540359B1 (ko) 2023-06-02
AU2017306692B2 (en) 2022-08-04
EP3494123B1 (en) 2024-09-25
EP4364808A2 (en) 2024-05-08
MY199749A (en) 2023-11-21
KR20230025949A (ko) 2023-02-23
ECSP19015395A (es) 2019-06-30
IL264575A (en) 2019-02-28
US20230355651A1 (en) 2023-11-09
CL2021001195A1 (es) 2021-10-22
KR20190038606A (ko) 2019-04-08
JP2023123469A (ja) 2023-09-05
US20210100829A1 (en) 2021-04-08
AU2022205929A1 (en) 2022-10-06
CO2019002017A2 (es) 2019-05-31
EP4364808A3 (en) 2024-07-31
KR20230084607A (ko) 2023-06-13
MX2020011806A (es) 2020-12-07
JP7625637B2 (ja) 2025-02-03
KR102774202B1 (ko) 2025-02-26
IL264575B1 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
US11517584B2 (en) RNAi agents for Hepatitis B virus infection
CN113507920A (zh) 用于乙型肝炎病毒感染的RNAi剂
HK40106715A (en) Rnai agents for hepatitis b virus infection
HK40009558B (en) Rnai agents for hepatitis b virus infection
HK40009558A (en) Rnai agents for hepatitis b virus infection
OA19828A (en) RNAi agents for hepatitis B virus infection
HK40062579A (en) Rnai agents for hepatitis b virus infection
HK40009627A (en) Rnai agents for hepatitis b virus infection
HK40009627B (en) Rnai agents for hepatitis b virus infection
NZ790939A (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
EA044937B1 (ru) АГЕНТЫ РНКи ПРОТИВ ИНФЕКЦИИ, ВЫЗВАННОЙ ВИРУСОМ ГЕПАТИТА В
NZ790940A (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17837738

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019505172

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3032945

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019002117

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017306692

Country of ref document: AU

Date of ref document: 20170804

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197006273

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2019/0002017

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2017837738

Country of ref document: EP

Effective date: 20190304

WWP Wipo information: published in national office

Ref document number: NC2019/0002017

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112019002117

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190201

WWG Wipo information: grant in national office

Ref document number: NC2019/0002017

Country of ref document: CO